microRNA-based identification of pulmonary signaling pathways in experimental asthma by Bartel, Sabine
 
  
 Aus dem 
Institut für Molekulare Immunologie 
Kom. Direktor: Prof. Dr. Ralph Mocikat 
Comprehensive Pneumology Center 
Direktor: Prof. Dr. Oliver Eickelberg 
des Helmholtz Zentrum München 
 
microRNA-based identification of pulmonary signaling 
pathways in experimental asthma - 
The role of the cAMP responsive element binding protein 
(Creb1)  
 
 
Dissertation 
 zum Erwerb des Doktorgrades der Naturwissenschaften 
an der Medizinischen Fakultät  
der Ludwig-Maximilians-Universität München 
vorgelegt von 
Sabine Bartel 
aus Dachau 
2015 
 
Mit Genehmigung der Medizinischen Fakultät 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
Betreuerin:  Prof. Dr. rer. nat. Elfriede Nößner 
Zweitgutachter:  Prof. Dr. rer. nat. Peter Jon Nelson 
Dekan:  Prof. Dr. med. Dr. h.c. Maximilian 
Reiser, FACR, FRCR 
Tag der mündlichen Prüfung:  30.04.2015 
 
 
 
 
 
 
 
 
 
 
Nothing, 
worth having in this world, 
comes easily! 
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I 
ZUSAMMENFASSUNG 
Asthma ist die häufigste chronische Erkrankung bei Kindern und sie ist in ihrer Prävalenz und 
Inzidenz über die letzten Jahrzehnte stark angestiegen. Das Krankheitsbild an sich ist bis zum 
heutigen Zeitpunkt intensiv erforscht worden, wobei über die Entstehung von Asthma im 
Kindesalter noch wenig bekannt ist. Aus diesem Grund ist es wichtig, neue Signalwege zu 
identifizieren, die für die Asthmaentstehung relevant sind, auch um daraus eventuell neue 
therapeutische Ansätze oder präventive Strategien zu entwickeln.  
Dafür haben wir microRNAs (miRNA) verwendet, die oft mehrere Schlüsselfaktoren in 
denselben Signalwegen regulieren. In vorrangegangener Arbeit hat unsere Gruppe gefunden, 
dass pulmonale miR-17 und miR-144 bei Ovalbumin (OVA) -induziertem experimentellen 
Asthma in Mäusen erhöht sind, und, dass sie den Transkriptionsfaktor „cAMP-responsive 
element binding protein“ (Creb) regulieren können. In dieser Arbeit haben wir nun weitere 
Bindestellen für miR-17 und -144, sowie auch für die neu miteinbezogene miR-21, in den 
3’UTRs von Creb1 Co-Aktivatoren (Crtc1-3) gefunden und in in vitro Experimenten validiert. 
Sowohl Creb1 als auch die drei Crtcs waren in Lungengewebe von Tieren mit experimentell 
induziertem Asthma durch OVA und Hausstaubmilben (HDM) verringert. Weiterhin haben 
wir die Expression eines möglichen Creb1 Zielgenes, Sec14-like 3 (Sec14l3), untersucht, 
welches ebenfalls in beiden Asthma Mausmodellen im Lungengewebe herunterreguliert war. 
Außerdem war der Verlust an Sec14l3 Protein in der Lunge mit der Hyperplasie von Mucus-
produzierenden Becherzellen assoziiert. In der Kultur von primären humanen Bronchialzellen 
(NHBE) führte eine Behandlung mit IL-13 zu einer transienten Herunterregulierung von 
Creb1, den Crtcs und Sec14l3. miR-17, -144 und -21 wurden nach IL-13 von diesen 
Primärzellen vermehrt in Exosomen sekretiert und diese konnten von Bronchialepithelzellen, 
und T Zellen aufgenommen werden. Die drei miRNAs konnten auch in Exosomen aus 
Nasenspülungen von Kindern mit allergischem Asthma und in bronchoalveolarer Lavage in 
Mäusen mit experimentellem Asthma gefunden werden. In nasalen Epithelzellen von Kindern 
mit allergischem Asthma waren miR-17, -144 und -21 stark erhöht und das Zielgen SEC14L3 
herunter reguliert.  
Alles in Allem, haben wir in dieser Arbeit eine neue molekulare Achse (miRNA-Creb/Crtc-
Sec14l3) gefunden, die relevant sein könnte für die Asthmaentstehung bei der Maus aber auch 
bei Kindern. Die Sekretion der miRNAs in Exosomen könnte die Reaktion der Zellen auf 
asthmatische Stimuli auf mehrere, verschiedene Zelltypen verteilen.  
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II 
SUMMARY 
Asthma is characterized by chronic airway inflammation; mucus hypersecretion and episodes 
of airway obstruction. It is the most common chronic disease in children and its incidence and 
prevalence have been markedly increasing over the last few decades. While the 
pathophysiology has been intensively studied, the underlying causes for asthma development 
remain largely unknown. Hence there is an unmet, clinical need to identify novel, so far non-
characterized pathways, relevant for this disease, to establish new therapies or preventive 
approaches.  
We used miRNAs to do so as they are critical regulators of key molecules within signalling 
pathways. Our group previously identified a pulmonary increase of miR-17 and -144 in 
ovalbumin-induced allergic airway inflammation in mice and they were shown to target the 
transcription factor cAMP-responsive element binding protein 1 (Creb1). In this work, we 
found and validated additional binding sites for the two miRNAs and the newly included miR-
21 in the 3’UTR of Creb1 co-activators CRTC1, -2 and -3. Creb1 and the three Crtcs were 
further shown to be down-regulated in two models of murine experimental asthma (ovalbumin 
and house dust mite). We postulated that a joint down-regulation of Creb plus its co-activators 
by the miRNAs might have detrimental, additive effects on the expression of target genes. In 
this respect, we identified the putative Creb1 target gene Sec14-like 3 (Sec14l3) which was 
down-regulated in both models for murine experimental asthma and its loss seemed to be 
associated with goblet cell metaplasia.  
Furthermore, we found that IL-13 treatment of primary normal human epithelial (NHBE) cells 
led to a decrease of CREB1/CRTCs and SEC14L3, while the latter correlated with 
forkheadbox protein J1 (FOXJ1), a marker for ciliated cells. miR-17, -144 and -21 were 
actively secreted into exosomes by the primary NHBE cells upon IL-13 stimuli, which could 
be uptaken by a bronchial epithelial cell line and a T cell line . We could also detect miRNA-
containing exosomes in nasal washes from children with allergic asthma and broncho-alveolar 
lavage fluid of mice with OVA-induced allergic airway inflammation. 
In nasal epithelial cells of children with allergic asthma, the three miRNAs were highly 
increased compared to healthy controls, while SEC14l3 expression was reduced.  
In conclusion, this work identified a novel molecular axis (miRNA-Creb/Crtc/Sec14l3) 
relevant for murine and paediatric asthma and gives first hints that miR-17, -144 and -21 in 
exosomes might be able to perpetuate the asthmatic response between different cell types. 
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1. INTRODUCTION 
1.1. Asthma 
1.1.1. The increasing burden of asthma 
Asthma is a chronic inflammatory lung disease affecting approximately 30 million people of 
different ages in Europe (1). It is the most common chronic disease in children that usually 
persists into adulthood. 
According to the European Lung White Book the prevalence in Europe in adults is highest in 
the UK (10-13%) and lowest in Georgia (0.28%) (1). In Germany, the number of people 
suffering from asthma is estimated at 4 million. Of note, the prevalence of asthma, and also 
allergy, has markedly increased over the last few decades in westernized countries (2). In 
Western Europe, it has doubled in the last ten years (1) and according to the Global Initiative 
for Asthma (GINA), the number of people suffering from asthma worldwide will further 
increase over the next two decades (3).  
The main symptoms are recurring episodes of breathlessness, chest tightening, wheezing and 
coughing. Of note, until puberty boys are more likely to develop asthma-like symptoms, 
which changes in adulthood, where women are more affected than men (4). Severe asthma 
can lead to irreversible airway remodeling and, thus, persistent respiratory dysfunction, which 
may already occur in very young children (5). 
Thus, the disease asthma represents a huge burden for the healthcare systems due to 
medications, hospitalizations and also absence from work. The total cost of asthma in Europe 
was estimated to amount to € 17.7 billion per year (1) with the majority caused by severe 
uncontrolled asthma. Thus, there is an urgent need for improved therapies, both from the 
perspective of patients and the health care system.  
 
1.1.2. Environmental influences on asthma development 
The lung, and especially the bronchial epithelium, represent the first barrier to the outside 
world and therewith beyond others allergens, pollutants, toxins, microorganisms. While the 
pathogenesis of asthma is in part well understood, the underlying causes for asthma 
development remain unknown. Asthma and allergy are generally associated with a 
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westernized lifestyle and are more prevalent in developed countries, an effect that cannot be 
explained by genetic predisposition alone. Therefore, it is intriguing to speculate that the 
environment does influence the development of these diseases.  
Proposed explanations are that modern housing and more time spent indoors has increased the 
exposure to house dust mite. Second, due to increased hygiene and the use of widespread 
antibiotics, we are exposed to a smaller variety of microorganisms – the so called hygiene 
hypothesis (reviewed in (2)). Third, the western diet has changed over the last few decades 
and the prevalence of obesity, especially in children, has increased (reviewed in (2)). Besides, 
various other factors like mode of delivery at birth (6), race or ethnicity (7), sex (8) and birth 
order (9), breastfeeding (10), keeping pets (11,12), viral (13,14) and bacterial infections (15), 
environmental tobacco smoke (16,17), and air pollution (18), have been shown to influence 
asthma risk. On the other hand, the environment can also protect from asthma, especially 
observed for (also in utero) exposures to a farming environment (19,20). 
Several studies have also shown that not only the post-natal environment can influence the 
asthma risk, but also the fetal development represents a fragile, susceptible period for early 
programming. Hence, an in utero exposure to, e.g. allergens (21,22), maternal and grand-
maternal smoking (23,24), but also the presence of maternal asthma (25), have been discussed 
to be important risk factors for the development of allergies and asthma later in life.  
In summary, the underlying causes for the development of asthma need to be further 
investigated to identify early developmental windows for interventions to prevent the disease 
development.  
 
1.1.3. Current therapy for asthma 
Despite intensive research, the therapeutic options for asthma have remained limited and 
cannot prevent airway remodeling, which may already occur in wheezing preschool children 
(5). The majority of asthma cases can be controlled by inhaled anti-inflammatory gluco-
corticosteroids and β2-receptor agonists. However, about 10% of all patients suffer from 
severe asthma with recurring exacerbations and the need for hospital and emergency room 
visits (1). So far, treatment is based on disease severity and control, rather than on the 
underlying mechanisms. To overcome this, several animal studies have been performed, 
showing promising results in using biological agents like monoclonal antibodies against IgE 
(26) or Th2 cytokines contributing to the asthma pathogenesis, like IL-5, IL-4 and IL-13 (27–
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29). However, clinical studies with anti-IgE (30), anti-IL-5 (31,32), anti-IL-4 receptor (33) 
and anti-IL-13 (34) have overall shown limited efficacy in humans, hence being effective only 
in a small subgroup of patients, which is most likely due to the heterogeneity of human 
asthma. 
Thus, there is a high and unmet clinical need to identify novel molecular pathways involved 
in the pathogenesis of asthma that can be used for therapeutic approaches.  
 
1.1.4. Pathogenesis of asthma –current concepts 
Asthma is not a single disease but rather a syndrome consisting of several different endotypes 
and phenotypes. General disease hallmarks are a chronic inflammation of the conducting 
airways, episodes of airflow obstruction associated with airway hyper-responsiveness (AHR), 
and mucus hyper-secretion. Along disease progression, the release of potent inflammatory 
mediators and also, in part, remodeling of the airway wall with smooth muscle cell hyper-
proliferation, sub-epithelial fibrosis and goblet cell metaplasia can lead to chronic respiratory 
dysfunction (reviewed in (35)).  
The most intensively studied phenotype, the so called allergic asthma, is characterized by a T-
helper (Th) 2-mediated eosinophilic inflammation (reviewed in (36)). However, there are 
many different endotypes for asthma with different pathogenesis. For example, some 
subforms of severe, steroid-resistant asthma have been associated with Th17 cells and 
neutrophilic inflammation (37). 
In general, asthma results from an allergic hypersensitivity, namely atopy, occurring mainly in 
childhood, against a normally harmless environmental substance such as house dust mite 
(HDM), animal dander, pollen or fungal spores (reviewed in (38)). In the lung, inhaled 
allergens, microorganisms and pollutants will first encounter the airway epithelium. Current 
concepts propose that this physical barrier to the outside can be damaged by infections, e.g. 
viruses enabling allergens to penetrate (reviewed in (39)), or can be attacked by proteases 
present in allergens themselves (reviewed in (38)). Upon first perturbation of this barrier, the 
epithelial cells secrete ‘danger signals’ like granulocyte-macrophage colony-stimulating 
factor (GM-CSF), thymic stromal lymphopoetin (TSLP), IL-25 and IL-33 (reviewed in (38)). 
The additional secretion of chemokines will attract immature antigen presenting cells (APC), 
namely dendritic cells (DC), towards the epithelium and the underlying mucosa (reviewed in 
(35)). The DCs will then take up and present the allergens to CD4 and CD8 T cells after 
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migrating to the draining mediastinal lymph nodes (Fig. 1.1) (reviewed in (40)). In allergic 
individuals, this process is enhanced as allergen can directly bind to its specific 
immunoglobulin E (IgE) molecules – derived from antigen specific B cells or plasma cells - 
that are attached to high affinity IgE receptors (Fcε-receptor I) on the DC surface (reviewed in 
(41)). This process can occur after penetration of the epithelium or even outside, as DCs can 
reach through the epithelial barrier with their dendrites to catch allergens via the IgE receptors 
(Fig. 1.1) (42). Presentation of the antigen to naïve and memory T cells in the lymph nodes 
leads to their polarization and maturation towards Th2 or also Th17 cells, depending on the 
cytokine environment. IL-4 from basophils for example skews naïve T cells towards a Th2 
phenotype (reviewed in (38)). Those T cells can then migrate to the epithelium and modulate 
the allergic response via secreting pro-inflammatory cytokines such as IL-4, IL-5 and IL-13 
for Th2 cells or IL-17 for Th17 cells. IL-4 and IL-13 for example can induce a class-switch 
towards IgE in B cells and a metaplasia of mucus-producing goblet cells in the airway 
epithelium (reviewed in (43)). IL-5 is involved in the recruitment of eosinophils to the 
airways (44). A relatively new cell type, the so called innate lymphoid cells (ILCs), which are 
lineage negative, can also contribute to asthma by secreting IL-5 and IL-13 after TSLP 
stimulus (reviewed in (38)). 
 
 
Figure 1.1: Simplified scheme of the interaction between the epithelium and the immune cells in allergic asthma. Upon 
exposure to allergen, the airway epithelium will secrete pro-inflammatory factors, such as granulocyte-macrophage colony-
stimulating factor (GM-CSF), thymic stromal lymphopoetin (TSLP) and IL-33, beyond others. Dendritic cells can uptake 
allergens and present them to naïve T cells in the local lymph node, which induces a context-dependent differentiation. In 
asthma, this is mostly skewed towards a Th2 phenotype. The Th2 cells then expand and migrate towards the epithelium, 
while secreting cytokines such as IL-4, IL-5 and IL-13, leading to IgE production by B cells, recruitment of eosinophils and a 
hyperplasia of mucus-producing goblet cells in the epithelium. Adapted from (35,45). 
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The role of the airway epithelium in the perpetuation of allergic airway disease comes more 
and more into the focus of asthma research. It has been shown that its physical barrier 
function is intrinsically impaired due to an opening of the tight junctions that keep bronchial 
epithelial cells together, allowing allergens to penetrate (Fig.1.1) (39). This effect can be 
induced by Th-2 cytokines, especially IL-4 and IL-13 (46,47). The normal airway epithelium 
consists of ciliated cells, club cells, goblet cells and basal cells. Upon exposure to Th2 
cytokines, ciliated cells and club cells can transdifferentiate into goblet cells – the so called 
goblet cell metaplasia - resulting in mucus hypersecretion and, in severe cases, to airway 
obstruction by mucus plugging (reviewed in (45)). Additionally, airway epithelial cells 
express pattern recognition receptors (PRR) such as toll-like receptors (TLR) and nucleotide 
oligomerization domain (NOD) receptors (48). A binding of allergen to those receptors 
initiates a secretion of pro-inflammatory stimuli, like TSLP, IL-33 and GM-CSF by the 
epithelial cells, propagating cascades in the asthma pathogenesis like Th2 differentiation 
(reviewed in (45)). 
In summary, there is a complex interplay between the airway epithelium and the immune 
system in asthma that has not been fully elucidated at the moment and needs to be further 
investigated to understand underlying causes for asthma development.  
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1.2. miRNAs 
1.2.1. Biogenesis and function 
Environmental stimuli might influence the pathogenesis and development of asthma for 
example via microRNAs. These short, ~22nt long, non-coding single stranded RNAs can 
regulate gene expression by binding to the 3’UTR in the mRNA of their target genes with 
their so called seed sequence. They have been already shown to be essential for the 
development of the immune system (reviewed in (49)) and the lung (reviewed in (50)).  
miRNAs have been discovered in the nematode Caenorhabditis elegans (C. elegans) 21 years 
ago (51) and to this day around 1,872 human miRNAs have been identified 
(www.mirbase.org).  
Their biogenesis starts in the nucleus when the miRNA encoding genes are transcribed by the 
RNA polymerase II or III intro primary miRNA transcripts (pri-miRNA) (52–54). Both 
polymerases are differentially regulated and transcribe different miRNA families, enabling a 
huge variety of regulation already at this early stage (reviewed in (55)). Some miRNA 
families are located in genomic clusters and often transcribed simultaneously; however, they 
can also be independently regulated (43). The capped and poly-adenylated pri-miRNA forms 
a hairpin stem of 33 basepairs, two single-stranded flanking regions and a terminal loop (Fig. 
1.2) (reviewed in (55)). The two 5’ and 3’ arms of the pri-miRNA hairpin are then 
subsequently cleaved 11bp away from the single stranded RNA/double stranded RNA 
junction by the RNase III enzyme Drosha, after interaction with DiGeorge critical region 8 
protein (DGCR8) that determines the exact cleavage site (57). The resulting precursor miRNA 
(pre-miRNA) is exported to the cytoplasm where it is cleaved by a complex of the TAR 
RNA-binding protein (TRBP) and the RNase Dicer to its mature length of around 22nt (58). 
After dissociation of Dicer and TRBP, the duplex is separated by helicases into the functional 
guide strand, complementary to its target, and the passenger strand. The latter is degraded, 
while the two strands are distinguished by the thermodynamic stability of the base pairs at the 
two ends of the duplex: the strand with more stable base pairs will be discarded (59). The 
mature miRNAs then form the RNA-induced silencing complex (RISC) together with 
Argonaute proteins (Ago). A complimentary base-pairing of the miRNA with a respective 
target messenger RNA (mRNA), mostly in the 3’UTR, guides the RISC to either degrade, 
destabilize by deadenylation, or translationally inhibit the bound mRNA (60). 
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Figure 1.2: miRNA biogenesis and function. After transcription by RNA Polymerase II/III, the pri-miRNA is cleaved by a 
complex of Drosha and DiGeorge critical region 8 (DGCR8). The resulting precursor miRNA (pre-miRNA) is exported to 
the cytoplasm and further cleaved by Dicer and TAR RNA binding protein (TRBP) to a miRNA duplex. While the functional 
miRNA strand is incorporated into the RNA-induced silencing complex (RISC) with Argonaute 2 (Ago2), the passenger 
strand is degraded. The binding (perfect or imperfect) of an active RISC complex to its mRNA target leads to mRNA 
cleavage, deadenylation, or translational repression. Adapted from (55). 
 
In contrast to small interfering RNAs (siRNAs), miRNAs can bind their targets also with 
imperfect base pairing as long as this does not occur in the 2-8nt long so-called “seed region” 
(61). This also explains the wide variety of genes that can be targeted by one single miRNA. 
However, they tend to address several key regulatory molecules in cellular pathways, such as 
transcription factors (62–64). This simultaneous regulatory fine tuning of several pathway 
components can then lead to pronounced downstream effects. 
 
1.2.2. Extracellular miRNA transport in exosomes 
The detection of miRNAs in serum and plasma gave rise to the idea that they might exert a 
biological function outside their cell of origin and can also be exploited as biomarker for 
diseases (reviewed in (65)). While a grand proportion of extracellular miRNAs is bound to 
Ago proteins and most likely is released from dying cells, some miRNAs are present in so 
called exosomes. Exosomes are small (30-90nm), very stable membrane vesicles of 
endosomal origin that are actively secreted from both immune cells and also structural cells in 
the lung (66–69). The biogenesis of exosomes starts with endocytic vesicles that form at the 
plasma membrane and then fuse to form early endosomes. After maturation to late 
endosomes, intraluminal vesicles budd off into the lumen resulting in multivesicular bodies 
(MVB) (reviewed in (70)). After fusion of MVBs with the cell membrane, exosomes are 
INTRODUCTION 
 
8 
released into the extracellular environment. Up to now, the mechanism of miRNA packaging 
into exosomes is not fully understood but seems to depend on the association of RISC 
complexes with the MVBs (reviewed in (65)). As the composition of miRNAs differs 
between exosomes and the originating cells, they seem to be specifically packaged (71). 
Besides miRNAs, exosomes also carry mRNA, enzymes or proteins such as major-
histocompability complex (MHC) proteins (71), and their composition corresponds to their 
cellular origin. Exosomes can be characterized by specific surface molecules, especially 
tetraspanins such as CD9, CD81 and CD63 or MHCII (71). 
Fusion of the exosomes with target cells or internalization by endocytosis is often guided by 
target cell-specific receptor molecules and allows for directed transfer of internal components 
and, in particular, functional transfer of miRNAs. Thus, they can be considered as a means of 
inter-cell-communication (reviewed in (72)). 
miRNA-containing exosomes have already been found in a variety of body fluids, such as 
saliva, plasma, breast milk (73) and broncho-alveolar lavage fluid (BALF) (74). The 
distribution of miRNA through exosomes to multiple cell types throughout the body increases 
the complexity of how cells communicate in health and disease.  
 
1.2.3. A role for miRNAs in asthma 
To this day, miRNAs have been shown to be of utmost importance in normal physiological 
processes like development, growth, differentiation and programmed cell death (49,75–78). A 
dysregulation of miRNAs has been observed and proven to be important in complex diseases 
like cancer (79). Regarding asthma, the miRNA expression in airways of patients with asthma 
has been shown to be altered compared to healthy controls (80,81). Several distinct miRNAs, 
namely miR-145 (82), miR-126 (83), miR-106 (84), let7 (85) and miR-21 (86,87) that target 
asthma-relevant molecules, like IL-13 (let-7) or IL-12p35 (miR-21), have been identified to 
be dysregulated in murine experimental asthma models and were targeted in a preventive 
setting. Thereby, the miRNAs were inhibited during or before the induction of the allergic 
airway inflammation but not therapeutically in established disease. This questions the 
relevance for treatment of human asthma where the patients already suffer from advanced 
disease at the time of diagnosis and preventive treatments are hardly possible.    
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1.3. The transcription factor cAMP-response element binding protein (Creb) 
1.3.1. Gene and protein structure 
The cAMP-response element binding protein (Creb) is a central transcription factor involved 
in many biological processes such as metabolism, neurotransmission, cell cycle, immune 
regulation and development (reviewed in (88)). Creb-/- mice seem fully developed but die at 
birth from respiratory failure due to pulmonary atelectasis and show impaired fetal T cell 
development (89), making this gene an interesting target to study in inflammatory lung 
disorders such as asthma. 
CREB1 is encoded on chromosome 2 of the human genome and has 17 splice variants, 10 of 
which are protein coding. The most prominent transcript variant is 7650 bp of length and 
consists of nine exons. In mice, Creb1 is located on chromosome 1, features 11 splice 
variants, six being protein coding and the main transcript has 8364 bp and eight exons.  
In mammalian systems, the Creb family of cAMP-responsive activators consists of Creb, the 
activating transcription factor 1 (Atf1) and the cAMP response element modulator (Crem). 
Creb and Atf1 are ubiquitously expressed throughout the body, Crem expression is highest in 
neuro-endocrine tissues (reviewed in (88)). The family members have a similar modular 
protein structure: it includes a basic leucine zipper (bZIP) domain at the carboxy-terminus that 
is required for DNA-binding and dimerization, and an amino-terminal transactivation domain 
(TAD) (Figure 1.3) (reviewed in (90)). The latter is required for the response to cAMP and 
consists of a central 60 amino-acid kinase-inducible domain (KID) and a glutamine-rich (Q2) 
constitutive activation domain, which can enhance transcription by binding the TBP-
associated factor 4 (TAF4) (reviewed in (90)). Outside of the TAD domain towards the N-
terminus there is another glutamine-rich domain (Q1) functioning, together with Q2, as 
constitutive activators in vitro (reviewed in (88)). In contrast, the KID domain is activated 
only after phosphorylation in response to cAMP and calcium (91). 
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Figure 1.3: Schematic protein structure of Creb. Creb and family members have a similar modular organization, 
containing two Gln-rich domains (Q1+Q2) that function as constitutive activators, a kinase-inducible domain (KID) with 
inhibitory phosphorylation sites for Atm at Ser109, Ser111, Ser114, Ser117, Ser121 and for CamkII at Ser142 and Ser143 
that hinder Cbp/p300 binding. Phosphorylation at Ser133 by Pka/Pkc favors Cbp/p300 binding hence activates transcription. 
KID plus Q2 domain that can bind TAF represents the transactivation domain (TAD). The bZIP domain at the C-terminus is 
required for DNA binding, nuclear localization and binding to Creb-regulated co-activators (Crtcs). Adapted from (90). 
 
1.3.2. Transcriptional regulation of Creb1 target genes 
Creb and its family members Atf1 and Crem were the first transcription factors shown to be 
activated by phosphorylation (reviewed in (88)). This was discovered roughly 25 years ago 
through the binding to the CRE element in the promoter of somatostatin, a neuropeptide gene 
(92–94). 
As indicated in the name, Creb is activated by phosphorylation upon cAMP stimulus. This 
prominent second messenger accumulates after activation of guanine-nucleotide-binding (G)-
protein coupled receptors, the synthesis being catalyzed by adenylyl cyclase (Ac) (95). cAMP 
then liberates the C subunit of protein kinase A (Pka), which under basal conditions resides in 
the cytoplasm as an inactive hetero-tetramer of paired regulatory (R) and catalytic (C) 
subunits. The free C subunit then diffuses into the nucleus and phosphorylates Creb at serine 
residue 133 in the KID domain (96). This recruits the Creb-binding protein (Cbp) and its 
paralogue p300, and Creb proteins bind as dimers to the DNA to initiate transcription 
(reviewed in 75). Cbp/p300 binding is required as it acetylates histones and also recruits the 
RNA polymerase II complexes (reviewed in (90)). This process usually takes about 30 min 
and lasts for two to four hours until Ser133 is dephosphorylated by the serine/threonine 
phosphatases Pp-1 and Pp-2A (reviewed in (88)). Of note, there are also other regulatory 
phosphorylation sites within the Creb KID domain that act inhibitory, such as Ser111 and 
Ser121, phosphorylated by ataxia-telangiectasia mutated (Atm) (97), and Ser142, targeted by 
calcium- and calmodulin-dependent kinase II (CamkII) (98). 
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Creb and family members initiate the target gene transcription by binding to cAMP response 
elements (CRE) at promoters. These can appear as palindromic (TGACGTCA) or half-site 
motifs (TGACG or CGTCA) (94). There are about 750,000 palindromic and half-site CREs 
present in the human genome, whereby the majority of them are unoccupied due to an 
inhibitory cytosine methylation of the CREB binding site (reviewed in (99)). The functional, 
non-methylated, sites are mostly localized to promoter proximal regions within 250 bp of the 
transcription start site and occur in about 5,000 genes (reviewed in (99)). However, even upon 
binding of phosphorylated Creb after cAMP stimulation, only a small number (~100) of genes 
are induced and this also strongly depends on the cell type (reviewed in (99)). This might be 
in part explained by the absence of canonical TATA boxes in two-thirds of Creb-occupied 
promoters that are required for transcriptional induction by cAMP (100). Additionally, some 
Creb binding sites might be epigenetically modified to limit accessibility. Finally, the 
transcription of Creb target genes in a cell-type or stimulus-specific manner is dependent on 
further activators.  
 
1.3.3. Creb Co-activators 
Indeed, recently a class of proteins, termed cAMP-regulated transcriptional co-activators 
(Crtc), has been identified that plays a role in modulating Creb target gene expression 
(101,102). This family consists of three members (Crtc-1, -2, and -3) with a similar modular 
structure: a C-terminal TAD domain, a splicing domain (SD), a central regulatory domain 
(REG), and a N-terminal Creb-binding domain that interacts with the bZIP domain of Creb 
(Fig. 1.4) (reviewed in (90)). 
 
 
Figure 1.4: Schematic protein structure of the Crtcs - exemplarily for Crtc2. Crtc1, -2 and -3 share a similar modular 
organization: an N-terminal Creb-binding domain (CBD), followed by the regulatory domain (REG) which entails three 
inhibitory phosphorylation sites at Ser171 (Ampk, Sik2), Ser275 (Mapk2) and Ser307 (Sik2) enabling binding to 14-3-3 
protein in the cytoplasm; an alternative splicing domain (SD) and an C-terminal transactivation domain (TAD). Adapted 
from (90). 
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In contrast to Creb, the Crtcs are under basal conditions sequestered in the cytoplasm, 
associated to 14-3-3 proteins via three phosphorylation sites, phosphorylated by either AMP-
activated kinase (Ampk), mitogen-activated protein kinase 2 (Mapk2) or salt-inducible kinase 
2 (Sik2) (reviewed in (90)). Dephosphorylation by calcineurin (Cn) is triggered by cAMP and 
calcium and leads to nuclear translocation of the Crtcs, which then bind together with Creb 
over relevant promoters (Fig. 1.5). This binding increases Creb occupancy on CRE sites (103) 
and thereby enhances transcription of target genes. Hence, the regulation of Creb target gene 
transcription can be seen as a two-hit model with first requiring phosphorylation of Creb itself 
and, second, the dephosphorylation and nuclear translocation of its co-activators (reviewed in 
(90)).  
 
Figure 1.5: The two-hit model for Creb/Crtc mediated regulation of transcription. Creb binds to CRE sites in promoter 
regions upon phosphorylation at Ser133 by protein kinase A (Pka) after cAMP stimulus and initiates target gene 
transcription. The Crtc proteins are sequestered in the cytoplasm. Upon cAMP accumulation, they are dephosphorylated by 
calcineurin (Cn) and translocate to the nucleus where they bind together with Creb over relevant promoters and further 
enhance gene transcription. Adapted from (90). 
 
Of note, there are numerous other factors that can interact with Creb to activate target gene 
transcription such as CBP or to repress it such as CREM. Alone 28 different factors are 
reviewed in (95). To investigate all of those would be out of the scope for this study, and 
hence they are not described in more detail.  
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2. AIMS AND OBJECTIVES 
In previous work of the group, dysregulated pulmonary miRNAs were identified in a murine 
model of ovalbumin-induced allergic airway inflammation. miR-17 and miR-144 were 
prioritized for further investigation and shown to target the transcription factor Creb1 (104). 
However, single miRNAs tend to target several critical regulators within a given pathway 
(62–64).  
Therefore, we hypothesized in the present work that miR-17 and miR-144 might also target 
other signaling components of the Creb1 pathway such as the co-activators Crtc1-3. We 
further postulated that a joint down-regulation of both Creb1 and Crtcs by miRNAs could lead 
to an additive, detrimental effect on the transcription of target genes and this could be relevant 
for the pathogenesis of asthma. 
 
In particular, we aimed to: 
• Identify and validate a possible binding of the dysregulated miRNAs to the Crtcs. 
• Evaluate the expression of the Creb1/Crtc pathway in murine experimental asthma. 
• Identify putative Creb1 target genes relevant for murine experimental asthma. 
• Study Creb/Crtc-mediated signaling during early asthmatic responses.  
• Investigate the relevance of the identified pathway for human paediatric asthma. 
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3. MATERIAL 
3.1. Chemicals and reagents 
Table 3.1: Chemicals and reagents 
 
Substance Manufacturer Country
4′,6-Diamidin-2-phenylindol (DAPI) Sigma-Aldrich St. Louis (USA)
Acetic Acid Carl Roth Karlsruhe (GER)
Adenosine triphosphate (ATP) pjk Kleinblittersdorf (GER)
Agarose Life Technologies Darmstadt (GER)
Albumin from chicken egg white, grade V (OVA) Sigma-Aldrich St. Louis (USA)
Ammoniumpersulfate (APS) Sigma-Aldrich St. Louis (USA)
Antibody diluent Zytomed Systems Berlin (GER)
BEGM Medium Lonza Wokingham (UK)
Bovine serum albumin (BSA) Sigma-Aldrich St. Louis (USA)
Bromphenolblue Merck Darmstadt (GER)
Citric Acid Monohydrate Carl Roth Karlsruhe (GER)
CML Latex 4% w/v 4 µm Life Technologies Darmstadt (GER)
Coelenterizine SynChem Illinois (USA)
Coenzym A pjk Kleinblittersdorf (GER)
cOmplete mini protease inhibitor cocktail Roche Mannheim (GER)
Dermatophagoides pteronyssinus extract (Nr. 218234) Greer Lenoir, USA
Dimethyl sulfoxide (DMSO) Sigma-Aldrich St. Louis (USA)
Dithiothreitol (DTT) pjk Kleinblittersdorf (GER)
D-Luciferin SynChem Illinois (USA)
ECL, ECL dura, ECL femto Thermo Fisher Scientific Waltham (USA)
Entellan Merck Darmstadt (GER)
Ethanol Merck Darmstadt (GER)
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich St. Louis (USA)
Exoquick-TC,  Exosome precipitation solution for culture media, 
spinal fluid and urine
System Biosciences San Francisco (USA)
Exosome-depleted FBS Media Supplement System Biosciences San Francisco (USA)
Fetal calf serum (FCS) Life Technologies Darmstadt (GER)
Fluorescence Mounting Medium Dako Hamburg (GER)
Formaldehyde solution 32 % Carl Roth Karlsruhe (GER)
Formamide Carl Roth Karlsruhe (GER)
Glycin PanReac Applichem Darmstadt (GER)
HBSS, 10x, Calcium, Magnesium, no Phenol Red Life Technologies Darmstadt (GER)
human placental collagen type IV Sigma-Aldrich St. Louis (USA)
Hydrochloric acid (HCl), 2 M Merck Darmstadt (GER)
Hydrogen peroxide (H2O2) Merck Darmstadt (GER)
Imject® Alum Thermo Fisher Scientific Waltham (USA)
Ketamin CD-pharma Québec (CAN)
Light Cycler 480 SYBR Green I Master Mix Roche Mannheim (GER)
Lipofectamine™ 2000 Life Technologies Darmstadt (GER)
Lyophilized exosomes from colon cancer cell line (COLO1) Hansa Biomed Tallin (EE)
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Substance Manufacturer Country
Magnesium carbonate (pentahydrate) (MgCO3)4Mg(OH)2 
*5H20
Carl Roth Karlsruhe (GER)
Magnesium sulfate (heptahydrate) MgSO4*7H2O Carl Roth Karlsruhe (GER)
Mayers Haematoxylin (hemalum solution) Merck Darmstadt (GER)
MEM (Minimal Essential medium) Life Technologies Darmstadt (GER)
Methanol Carl Roth Karlsruhe (GER)
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma-Aldrich St. Louis (USA)
Na3VO4 Sigma-Aldrich St. Louis (USA)
NaF Sigma-Aldrich St. Louis (USA)
Paraffin 53-54° Carl Roth Karlsruhe (GER)
peqFECT DNA peqLab Biotechnolgies Erlangen (GER)
peqFECT siRNA peqLab Biotechnolgies Erlangen (GER)
periodic acid cristals Merck Darmstadt (GER)
Phosphate buffered saline (PBS) Life Technologies Darmstadt (GER)
PKH67 green fluorescent cell linker kit Sigma-Aldrich St. Louis (USA)
PneumaCult™-ALI medium StemCell technologies Köln (GER)
Prestained protein page ruler Thermo Fisher Scientific Waltham (USA)
psiCHECK™-2 Vector Promega Wisconsin (USA)
Qiazol lysis reagent Qiagen Hilden (GER)
recombinant murine Interleukin 13 R&D systems Wiesbaden (GER)
RestorePlus® Stripping buffer Thermo Fisher Scientific Waltham (USA)
RNAlater® Life Technologies Darmstadt (GER)
Rotiphorese® Gel 30 Carl Roth Karlsruhe (GER)
Schiff's reagent Merck Darmstadt (GER)
Sodium bicarbonate (NaHCO3) Merck Darmstadt (GER)
Sodium carbonate (Na2CO3) Sigma-Aldrich St. Louis (USA)
Sodium chloride (NaCl) Merck Darmstadt (GER)
Sodium dodecyl sulfate (SDS) GE Healthcare Chalfont St Giles (UK)
sodiumhydrogensulfite 39% Merck Darmstadt (GER)
Sulfuric acid (H2SO4) Carl Roth Karlsruhe (GER)
TaqMan® Universal PCR Mastermix, no AmpErase® UNG Life Technologies Darmstadt (GER)
Tricine Carl Roth Karlsruhe (GER)
Tris Carl Roth Karlsruhe (GER)
Triton X-100 Sigma-Aldrich St. Louis (USA)
Trypan blue Sigma-Aldrich St. Louis (USA)
Trypsin-EDTA Life Technologies Darmstadt (GER)
Tween 20 Sigma-Aldrich St. Louis (USA)
Xylazin aniMedica Senden-Bösensell (DE)
Xylene Merck Darmstadt (GER)
Xylol PanReac Applichem Darmstadt (GER)
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3.2. Buffers and solutions 
Table 3.2: Buffers and solutions 
 
Name Substance Volume
0.5M Tris-Cl, pH 6.8 Tris 15.41 g 
add H2O bidest 250 ml
1.5M Tris-Cl, pH 8.8 Tris 45.43 g
add H2O bidest 250 ml
Flow cytometry wash buffer 
(exosomes)
FBS (exosome depleted) 3%
add PBS 500 ml
6x Laemmli loading dye Tris 375 mM
DTT 600 mM
SDS 12%
Glycerol 60%
Bromphenolblue 0.06%
Citrate buffer (pH 6) Citric acid 2.1 g
add H2O bidest 1 l
Na-Tris (10x) Tris 60.5 g
Aqua dest. 700 ml
add Aqua dest. 1000 ml
NaCl 90 g
MES buffer Glycine 0.10%
sodium azide 0.10%
add PBS 500 ml
Lysis buffer (pH 7.4) Tris 15.14 g
Triton X-100 5 g
add H2O 500 ml
Periodic acid periodic acid cristals 0.5g
add H20 bidest 100ml
RIPA buffer Tris (pH 7.4-8) 50 mM
NaCl 150 mM
Triton X-100 1%
Sodiumdeoxycholate 0.5-1 %
NaF 5-10 mM
Na3VO4 1 mM
DTT 1 mM
Protease Inhibitor 1x
adjust pH to 7.2 with 2M HCl
adjust pH to 6.8 with HCl
adjust pH to 8.8 with HCl
adjust pH to 6 
Dissolve and adjust pH to 6.8
adjust pH to 7.6 with 2M HCl
add prior 
to use
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Name Substance Volume
Running Gel SDS Page (for 2 gels) H2O bidest 3.08 ml
Rotiphorese® Gel 30 
Acrylamid
3.3 ml
1.5 M Tris-Cl, pH 8.8 4.18 ml
10 % SDS in H2O 110 µl
10 % APS  in H2O 220 µl
TEMED 5.5 µl
Stacking Gel SDS Page (for 2 gels) H2O bidest 3 ml
Rotiphorese® Gel 30 
Acrylamid
650 µl
0.5 M Tris-Cl, pH 6.8 1.25 ml
10 % SDS in H2O 50 µl
10 % APS  in H2O 50 µl
TEMED 5 µl
Sulfite water sodiumhydrogensulfite 39% 100ml
add H20 bidest 300ml
TAE buffer (pH 8.5) Tris 242 g
Acetic acid 57.1 ml
EDTA, 0.5 M 100 ml
add H2O 1000 ml
TBE buffer (5x) Tris 54.51 g
Boric acid 27.51 g
EDTA-Na2 4.65 g
add H2O 1000 ml
prior to 
use
add 
directly 
before 
usage
pour between two glass plates and cover surface 
with H2O till dry
add 
directly 
before 
usage
pour on top of running gel and insert comb 
Dilute to 1x with H2O bidest
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Name Substance Volume
Western Blot 10x running buffer Tris 30 g
Glycin 144 g
SDS 10 g
add H2O 1l
prior to 
use
Western Blot 10x transfer buffer Tris 30 g
Glycin 141 g
add H2O 1l
prior to 
use
add MeOH 200 ml
 Western Blot 10x TBS Tris 12.1 ml
NaCl 40 g
add H2O 500 ml
Western Blot 1x TBST for 1 l 10x TBS 100 ml
H20 bidest 900 ml
add Tween 20 1 ml
Dilute to 800 ml 1x with H2O bidest 
Dilute to 1x with H2O bidest
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3.3. Antibodies 
Table 3.3: Antibodies 
 
  
Antibody 
Molecular 
Weight
Application Manufacturer Country
CREB rabbit mAB (#9197) 43 kDa Western Blot
Cell Signaling 
Technology
Danvers (USA)
CRTC1 rabbit mAB (#2587) 80 kDa Western Blot
Cell Signaling 
Technology
Danvers (USA)
CRTC3 rabbit mAB (#2720) 78 kDa Western Blot
Cell Signaling 
Technology
Danvers (USA)
GAPDH rabbit mAB (#2118) 37 kDa Western Blot
Cell Signaling 
Technology
Danvers (USA)
FOXJ1 mouse mAB (#365216) 55 kDa
Western Blot, 
Immunofluorescence
Santa Cruz Biotech Dallas (USA)
SEC14l3 rabbit pAB (ab113799) 46 kDa
 Western Blot, 
Immunofluorescence 
(mouse)
Abcam 
Cambridge 
(USA)
Immun-Star Goat anti-rabbit HRP-
conjugate IgG
 - Western Blot Biorad Hercules (USA)
Alexa-Fluor 568 goat anti-rabbit 
IgG (H+L) 
 - Immunofluorescence Life Technologies
Darmstadt 
(GER)
Purified mouse anti-human CD63 
(#556019)
25kDa flow cytometry BD Biosciences
Franclin Lakes 
(USA)
Purified  anti-mouse CD63   
(#143901)
25kDa flow cytometry Biolegend
San Diego 
(USA)
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3.4. Oligonucleotides 
All oligonucleotides were synthesized by Metabion International AG (Martinsried, Germany). 
Prior to use, they were validated for specificity by melting curve analysis and gel 
electrophoresis and tested for efficiency.  
 
Table 3.4: Primer sequences used for qRT-PCR 
 
Table 3.5: miRNA mimics 
 
Gene name Species  fwd 5'->3' rev 5'->3'
CRTC1 hsa GAATCCTTTAGCAGTGGGTCC TTTGTCTGCCTCTGATGTGG
CRTC2 hsa GACAAGCTCTGACTCTGCCC CCATCCAGAATACCCCCAC
CRTC3 hsa AGATGTGGGTTTTGACCAGC TGTTGAGGTCTTTGAACAGGC
SEC14l3 hsa CAAGGGGTTGCTCTTCTCAG TCCCTAGCCTCTCTGTCTGC
MUC5AC hsa GCCTTCACTGTACTGGCTGAG AGGGTCTGAAGATGGTGACG
FOXJ1 hsa TCGTATGCCACGCTCATCTG CTTGTAGATGGCCGACAGGG
HPRT hsa TTGTTGTAGGATATGCCCTTGAC TCTCATCTTAGGCTTTGTATTTTGC
CREB1 mmu/hsa CCCAGCAACCAAGTTGTTGTT CTG CCT CCC TGT TCT TCA TTA GAC
Crtc1 mmu CGGGCTCCACACTCAACTA TGCTCAGTTCCTTAGAGAGGCT
Crtc2 mmu GTACAACGAGATGCCCGC CTAAACAACTGCCCCTTCTCAG
Crtc3 mmu GCATGAGTGTGGGGAACAG TGGATGGAAGGGTTACTTCG
Sec14l3 mmu CATGTGTCAGCGAAATCCC TCTATGTCAATGCAGCGAGTG
Hprt mmu CAGGCCAGACTTTGTTGGAT ACGTGATTCAAATCCCTGAAGT
miRNA analysis
TaqMan® miRNA-Assays miRNA Sequence Provider
hsa/mmu-miR-17 CAAAGUGCUUACAGUGCAGGUAG
Life technologies, 
Darmstadt (GER)
hsa/mmu-miR-144 UACAGUAUAGAUGAUGUACU
Life technologies, 
Darmstadt (GER)
hsa/mmu-miR-21 UAGCUUAUCAGACUGAUGUUGA
Life technologies, 
Darmstadt (GER)
miRNA mimics
negative control (scrambled 
miRNA)
Ambion® Pre-miR™ Precursors
Life technologies, 
Darmstadt (GER)
hsa/mmu-miR-17 Ambion® Pre-miR™ Precursors
Life technologies, 
Darmstadt (GER)
hsa/mmu-miR-144 Ambion® Pre-miR™ Precursors
Life technologies, 
Darmstadt (GER)
hsa/mmu-miR-21 mir Vana® miRNA mimics
Life technologies, 
Darmstadt (GER)
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3.5. Commercial kits 
Table 3.6: Commercial kits 
 
3.6. Cell lines and mouse strains 
Table 3.7: Cell lines 
 
Table 3.8: Mouse strains 
 
Kit Provider Country
BCA protein assay kit
Thermo Fischer 
Scientific
Waltham (USA)
Clonetics™ ReagentPack™ Lonza Wokingham (UK)
Diff-Quick kit Medion Diagnostics Düdingen (CH)
Exosome CD63 ELISA
Systems 
Biosciences
San Francisco 
(USA)
miRNeasy micro kit Qiagen Hilden (GER)
miRNeasy mini kit Qiagen Hilden (GER)
Quantitect Reverse Transcription kit Qiagen Hilden (GER)
TaqMan® miRNA reverse 
transcription kit
Life Technologies Darmstadt (GER)
cell line origin Provider
16HBE14o-
 Isolated from human bronchial epithelium. 
Transformed with SV-40 virus
Dieter C. Gruenert
MLE-12
murine transgenic lung epithelial cells, 
transformed with  SV-40 virus
ATCC; LGC Standards, 
Wesel (GER)
NHBE
primary normal human bronchial epithelial cells 
from cadavers
Lonza, Wokingham (UK)
Strain Provider Country
Balb/c Charles River Sulzfeld (GER)
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3.7. Miscellaneous consumables 
Table 3.9: Miscellaneous consumables 
 
3.8. Software and websites 
Table 3.10: Software and websites 
 
 
Consumables Provider Country
6 & 12 well plates Nunc™ Thermo Fischer Scientific Waltham (USA)
12-well transwell inserts (clear, 0.4µm) Corning New York (USA)
12-well transwell inserts (transparent, 
0.4 µm)
Greiner Bio-One Frickenhausen (GER)
Cell culture flasks 75cm2, 175cm2 Greiner Bio-One Frickenhausen (GER)
Cell scraper 240m, blade width 13mm TPP Trasadingen (CH)
Cryotubes Sarstedt Nürnbrecht (GER)
Glass slides Gerhard Menzel Braunschweig (GER)
Histology cassettes Thermo Fischer Scientific Waltham (USA)
LumiNunc, F96 Thermo Fischer Scientific Waltham (USA)
Microplate 96 well Greiner Bio-One Frickenhausen (GER)
Mini-PROTEAN® Tetra Cell 1D 
electophoresis system
Biorad Hercules (USA)
qPCR plate Biozym Hessisch-Oldendorf (GER)
Shandon cytofunnels Thermo Fischer Scientific Waltham (USA)
Software Source
Axio Vision Zeiss, Oberkochen (GER)
GraphPad Prism v5.0 GraphPad Prism Software, San Diego (USA)
LightCycler® 480 Software v1.5 Roche, Mannheim (GER)
Target Scan www.targetscan.org
miRbase www.mirbase.org
MatInspector Release professional 8.0.5, 
March 2011 
(Database version: ElDorado 08-2011; MatInspector library: Matrix Family 
Library Version 8.4 (June 2011))
ImageLab™ v5.1 Biorad, Hercules (USA)
Flow Jo v10 FlowJo, Ashland (USA)
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3.9. Equipment and devices 
Table 3.11: Equipment and devices 
 
 
Equipment/ device Name Provider Country
Centrifuges Mikro 200 Hettich Zentrifugen Tuttlingen (GER)
Mikro 200R Hettich Zentrifugen Tuttlingen (GER)
Rotina 420R Hettich Zentrifugen Tuttlingen (GER)
Cytospin centrifuge Cytospin 4 Thermo Fischer Scientific Waltham (USA)
Embedding Machine Microm EC350 Zeiss Oberkochen (GER)
Flow cytometer BD LSRII Becton Dickinson Franclin Lakes (USA)
Fluorescence plate reader Sunrise® Tecan Männedorf (CH)
Fridge/Freezer  4°C Liebherr Biberrach an der Riss (GER)
 -20°C Liebherr Biberrach an der Riss (GER)
 -80°C Eppendorf Hamburg (GER)
Fume Hood Airflow Control Vinitex Sint Oedenroede (NL)
Gel Imager ChemiDoc™ Imaging System Biorad Hercules (USA)
Hemocytometer Neubauer cell chamber GLW Würzburg (GER)
Homogenizer MagnaLyser Roche Mannheim (GER)
Homogenizer Polytron TP2100 Thermo Fischer Scientific Waltham (USA)
Incubator
Heraeus Function Line 
Incubator BDG220
Thermo Fischer Scientific Waltham (USA)
Liquid nitrogen tank  Apollo Cryotherm Kirchen/Sieg (GER)
Mastercycler Mastercycler Gradient Eppendorf Hamburg (GER)
Microscopes Axiovert 40c Zeiss Oberkochen (GER)
Axio Imager Zeiss Oberkochen (GER)
Microtom Hyrax M55 Zeiss Oberkochen (GER)
Nebulizer pari Boy Pari Starnberg (GER)
Platform shaker Duomax 1030 Heidolph Schwabach (GER)
Real-time Thermocycler Light Cycler 480 Roche Mannheim (GER)
Spectrophotometer Nanodrop ND-1000 PeqLab Biotechnology Erlangen (GER)
Sterile hood Herasafe KS Thermo Fischer Scientific Waltham (USA)
Tissue processor Microm STP420D Thermo Fischer Scientific Waltham (USA)
Water bath Aqualine AL12 Lauda Lauda-Königshofen (GER)
Western blot developer ChemiDoc™ Imaging System Biorad Hercules (USA)
Xray developer Curix60 Siemens Healthcare Sankt Wolfgang (GER)
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4. METHODS 
4.1. Mouse models 
4.1.1. Animal maintenance 
Female Balb/c mice were obtained from Charles River (Sulzfeld, Germany) and housed in 
individually ventilated cages. A standard pellet diet and water were provided ad libitum. The 
study was conducted under the federal guidelines for the use and care of laboratory animals 
and was approved by the Government of the District of Upper Bavaria. 
 
4.1.2. Induction of allergic airway inflammation 
Female 6 to 8 weeks old Balb/c mice were sensitized by six consecutive intra-peritoneally 
(i.p.) injections of ovalbumin (OVA) in alum (1µg in 200 µl PBS) or PBS in alum for controls 
on days 0, 7, 14, 28, 42, and 56. Allergic airway inflammation was triggered by two 
ovalbumin aerosol challenges (20min, 1% OVA in PBS) at day 70 and 71. Mice were 
sacrificed on day 29 or 72 (Fig. 4.1) Treatments were performed by Dr. Francesca 
Alessandrini (ZAUM, Munich) and the model is described in (105). 
 
 
Figure 4.1: Treatment scheme for OVA-induced allergic airway inflammation. 6-8 week old female Balb/c mice were 
sensitized intra-peritoneally (i.p.) six times with ovalbumin (OVA) in alum or PBS for control groups and then subjected to 
two consecutive OVA aerosol-challenges (1% OVA in PBS) on day 70 and 71. Animals were sacrificed either on day 29 or 
day 72. 
 
For house dust mite (HDM) induced asthma, mice were treated intra-nasally three times per 
week over five weeks with 20 µg Dermatophagoides pteronyssinus in 30 µl PBS or PBS only 
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for controls. Treatments were performed together with Petra Nathan, Katrin Milger and 
Jeremias Götschke (CPC Munich). 
 
Figure 4.2: Treatment scheme for HDM-induced allergic airway inflammation. 6-8 week old female Balb/c mice were 
treated three times per week over five weeks intra-nasally (i.n.) with either house dust mite extract (HDM) or PBS for 
controls. Animals were sacrificed 24 h after the last allergen challenge. 
 
4.1.3. Lung function 
Animals were injected i.p. with ketamine (140 mg/kg) and xylazine (7 mg/kg). When the 
anaesthesia was deep enough, the mice were tracheotomised and intubated with an 18G tube, 
placed on a warming plate and ventilated with a tidal volume of 10 ml/kg at a frequency of 
150 breaths/minute and a positive end-expiratory pressure of 2 cm H2O on a Buxco system 
(R/C system). To assess airway hyperreactivity (AHR), the mice were challenged with the 
broncho-constrictor metacholine in physiological saline generated with an in-line nebulizer 
and administered directly with increasing concentrations (0, 6.25, 12.5 mg/ml) by the 
ventilator for 20 seconds. Resistance (R) and Compliance (C) were measured continuously for 
2 min and the average was calculated and plotted against the concentration. Measurement was 
performed by Petra Nathan, Katrin Milger and Jeremias Götschke (CPC Munich). 
 
4.1.4. BAL analysis 
Broncho-alveolar lavage (BAL) was performed by three times intra-tracheal instillation and 
retrieval of 0.8 ml PBS. The cellular fraction was separated from the fluid by centrifugation 
for 10 min at 4 °C and 1200 rpm. The BAL fluid (BALF) was stored at -80 °C until further 
use while BAL cells were immediately further processed. 
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4.1.4.1. Total cell counts 
After resuspension of the BAL cell pellet in 160 µl of cold PBS (with 5% FCS), the cells were 
counted by using a hematocytometer, diluted1:1 with trypan blue. The total cell number was 
calculated with the following formula: total cell number = (counted cells in 4 squares / 4) * 2 
(* dilution) * 104/ml. 
 
4.1.4.2. Differential cell counts 
104 to 105 cells in 150 µl PBS (with 5% FCS) were transferred to a glass slide by 10 min cyto-
centrifugation at 400 rpm. The cytospins were dried over night at room temperature and 
subsequently stained with the May-Giemsa-Grünwald staining (Diff-Quick kit) according to 
the manufacture’s recommendations. The DNA-rich nuclei are stained dark blue or violet by 
the alkaline components methylene blue and azur B. The cytoplasm appears in light blue with 
dark blue granula for basophils and acidophilic pink eosin-stained granula in eosinophils. The 
granula in neutrophils are only week acidophilic and therefore are not visible in the stain. 
Furthermore, macrophages were distinguished from lymphocytes by their larger size and 
bigger cytoplasm. Differential cell counts were performed with a light microscope at a 40x 
magnification and at least 500 cells per slide were counted. 
 
4.2. Histopathology – Periodic Acid Schiff stain 
To analyze inflammation and lung structures, the left lung lobe was fixed by instillation of 4% 
paraformaldehyde (PFA) and immersion over 24 h at 4 °C. Afterwards, the tissue was 
incubated with 70% ethanol for up to three days in histology cassettes. In a tissue processor, 
washing steps with increasing concentrations of ethanol (ethanol 70%, 80%, two times 95%, 
two times 100%) were applied to dehydrate the tissue and it was washed two further times for 
5min with xylene. The transwell membranes of the NHBE primary cell cultures were first 
embedded in 2% agarose in HBSS to protect them during the dehydration process. 
Afterwards, the tissue was embedded in paraffin while the NHBE membranes were put in a 
vertical position to enable cross-sectioning. 3 µm thick sections were cut with a microtome, 
put on glass slides, air-dried and stored until further processing. For staining with either dyes 
or fluorescent antibodies, the paraffin was removed from lung slices by brief incubation in 
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xylol and a decreasing EtOH row (two times 2 min in 100%, 1 min in 90%, 1 min in 80%, 1 
min in 70% and 30 sec in H2O). 
A periodic acid Schiff stain was used to evaluate goblet cell metaplasia and mucus production 
in the murine lungs and the cross-section cut NHBE membranes. The stain is used to detect 
glycol groups that are oxidized by the periodic acid to aldehyde groups. These aldehyde 
groups can then bind the fuchsin sulfurous acid in the Schiff’s reagent, which results in a 
switch from colorless to bright pink. Hence, neutral muco-substances will be demonstrated in 
pink, while the nuclei are stained blue by hematoxylin.  
Briefly, the de-paraffinized sections were first incubated for 10 min in periodic acid, then 
washed 10 min with ddH20 and stained with Schiff’s reagent for another 10 min. Afterwards 
the sections were incubated three times for 5 min each in three different cuvettes with sulfite 
water and washed again for 10 min with ddH20. For staining of the nuclei, the sections were 
kept for 2.5 min in Mayer’s Hematoxylin, washed shortly first with ddH20 and then 0.3% HCl 
in 70% EtOH. After another 10 min wash with ddH20, the samples were dehydrated by an 
increasing alcohol row (3 times quickly dipping into 70% and 80% EtOH, then 1 min each in 
90%, 96% and 100% EtOH followed by 2 min in 100% EtOH and two times 5 min in xylol.  
Afterwards, the sections were covered with a coverslip and entellan and analyzed by light 
microscopy. The stainings were performed by Rabea Imker (CPC Munich).  
 
4.3. Cell culture 
4.3.1. Culture of different cell lines 
The transformed cell lines of murine lung epithelial cells (MLE-12) and human bronchial 
epithelial cells (16-HBE14o-) (106) were cultured in MEM medium supplemented with 10% 
FCS at 37°C and 5% CO2 without antibiotics under standard conditions. To detach the cells, 
they were incubated with 2 ml of trypsin for 5 min at 37°C or until the detachment was visible 
per microscopy. The reaction was stopped by addition of fresh media and the cells were 
transferred to new flasks or well plates. To determine the cell number, the cells were counted 
as described in 4.1.4.1. 
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4.3.2. Air-liquid interface culture of primary human bronchial epithelial cells 
Primary normal human bronchial epithelial cells were cultured in T25 cm2 flasks in BEGM 
medium at 37°C, 95% CO2 and 5% O2 in a humidified incubator. When the density reached 
80%, cells were passaged using the Clonetics™ ReagentPack™ for subculturing. The cells 
were washed with 5 ml of pre-warmed HBSS and detached with 2 ml pre-warmed 
trypsin/EDTA for 3 - 5 minutes on 37°C followed by gentle tapping the side of the flask. 
Trypsin was inactivated by addition of 4 ml pre-warmed TNS and the entire mixture was 
transferred to a tube. Residual cells were collected by rinsing the flasks with 2 ml of pre-
warmed HBSS. After pelleting the cells for 5 min at 220x g at room temperature, they were 
resuspended in 1 ml BEGM medium. Cell numbers were determined as described in 4.1.4.1 
and subsequently either frozen for cryopreservation or seeded for experiments. 
 
4.3.2.1. Differentiation of NHBE cells at the air-liquid interface 
For air-liquid interface experiments the NHBE cells were cultured on 12-well transwell 
inserts that were pre-coated with human-placental collagen type IV. Collagen type IV pre-
coating was performed with 8.9 µg/cm2. Collagen type IV, supplied as cotton ball, was 
dissolved in ddH20 / 0.2% acetic acid at 37 °C for 15 - 30 min to a concentration of 500 
µg/ml, aliquoted and stored at -20 °C. It was diluted with HBSS and 200 µl were added to 
each transwell insert and incubated for 3 hours at room temperature. Pre-coated inserts were 
either used immediately, or stored at 4°C. Prior to cell seeding, the remaining lid was 
aspirated and each well was washed with 500 µl HBSS and the membranes were exposed to 
UV light in the laminar flow hood for 30 minutes to ensure sterility. 
80,000 - 90,000 cells at passage 2 were seeded onto the pre-warmed human placental collagen 
type IV-coated 12-well transwell inserts in pre-warmed BEGM medium and expanded to 
confluency for approximately two days. Then, the apical medium was aspirated and the basal 
medium was changed to PneumaCultTM-ALI medium containing 1% penicillin/streptomycin 
to start the air-liquid interface culture (d0). For differentiation into a pseudo-stratified 
epithelium, the NHBE cells were left for 28 days (Fig. 4.3) with regular changes of the basal 
medium every two days. The apical mucus was removed by weekly washes with 500 µl of 
HBSS.  
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Figure 4.3: Differentiation of NHBE cells at the air liquid interface. Primary normal human bronchial epithelial cells 
were plated into 12-well transwell inserts (pre-coated with human collagen type IV) and expanded under submerged 
conditions. When the cells were fully confluent (typically after two days) the apical medium was aspirated (air-lift) and the 
cells were left to differentiate for 28 days with regular changes of the basal medium (every two days). 
 
4.3.2.2. Treatment of NHBE cells with IL-13 
In order to induce “asthma-like” changes to the bronchial epithelial cells including goblet cell, 
metaplasia and mucus hypersecretion, the cells were treated with interleukin-13 (IL-13). 
Therefore, 10 ng/ml of IL-13 (diluted in PBS) was added to the basal PneumaCultTM-ALI 
medium at d0 of airlift and at every consecutive medium change. After 24 hours, four days 
and seven days cells were sampled for RNA and protein expression analysis and histology 
(Fig. 4.4). Additionally, the apical side was washed with 500 µl of HBSS to collect secreted 
exosomes. This supernatant, as well as the basal medium, was frozen at –80°C until analysis. 
The NHBE cultures and IL-13 treatments were performed together with Andrea C. 
Schamberger (RG Oliver Eickelberg, CPC Munich). 
 
 
Figure 4.4: Induction of goblet cell metaplasia by IL-13 in NHBE cells. Primary normal human bronchial epithelial cells 
were plated into 12-well transwell inserts (pre-coated with human collagen type IV) and cultured under submerged 
conditions. When they reached confluency, the apical medium was aspirated (air-lift) and 10 ng/ml IL-13 was added to the 
basal medium, which was renewed every 2 days. Samples were taken at 24 hours, four days and seven days post air-lift. 
 
4.3.3. Cryopreservation 
In order to maintain low passage numbers, cells were frozen and stored in liquid nitrogen until 
further use. Therefore, cells were harvested by trypsination and 1-5 x 106 cells/ml were 
aliquoted into cryotubes in 1 ml of medium containing 20% FCS and 10% DMSO. The vials 
were slowly cooled down to -80°C by using a Mr. Frosty® freezing device filled with 
isopropanol. After two days, the cell vials were transferred to liquid nitrogen for long term 
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storage. To thaw cells, the frozen vials were warmed up to 37°C in a waterbath, pelleted by 
centrifugation and then seeded in appropriate fresh cell culture medium into a 75cm2flask. 
 
4.3.4. Transfection 
Transfection experiments were conducted with Lipofectamine 2000™ in 12-well plates 
following manufacturer´s instructions. PremiRs for miR-17, -144 and -21 were transfected in 
duplicates to a final miRNA concentration of 20 nM per well. Briefly, premiRs were mixed 
with Lipofectamine 2000™ in a 1.5 ml tube and incubated for 20 min. Afterwards, the 
mixture was added to the cells and further incubated for 72 h. The medium was changed after 
24 h to remove the lipid complexes and increase cell viability.  
 
4.4. Paediatric asthma samples 
4.4.1. Study population 
The expression of miRNAs and target genes was investigated in nasal epithelial cells and 
nasal washes from children diagnosed with allergic asthma, or healthy controls. The patients 
were participants in the Asthma Severity Modifying Polymorphisms (AsthMaP) Project, a 
study of asthma in urban children and adolescents based at the Children’s National Medical 
Center (Washington, DC, USA). The AsthMaP Project is described in detail elsewhere (107–
111). The collection and storage of study samples was done and provided by the laboratory of 
Prof. Dr. Robert J. Freishtat (Washington DC, USA). 
We included in this study 7 children with allergic asthma and compared those to 10 healthy 
children without history of asthma or wheezing as controls (Table 4.1). Inclusion criteria were 
a physician-diagnosed asthma, present at least for one year, elevated blood eosinophil counts (    
>4%) and serum IgE levels ( >398 U/ml). Age-matched, non-atopic healthy control samples 
were collected at the Princess Margaret Hospital in Subiaco (Australia).  
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Table 4.1: Patient demographics 
 
 
4.4.2. Isolation of nasal epithelial cells 
A cytology brush was used to obtain epithelial cells by brushing the medial aspect of the 
inferior turbinate of each nare. The samples were pooled in one container prior to isolation. 
The epithelial cells were isolated from the nasal brushings as follows. Briefly, the cytology 
brush was centrifuged in a 15 ml falcon tube containing 5 ml medium. The cells were then 
incubated in MEM medium containing 10% FCS and 1% P/S over night in 6-well plates. The 
next day, the epithelial cells were attached to the surface of the cell culture plate and other cell 
types could be removed by washing the plates with PBS. This was done and provided by the 
laboratory of Prof. Dr. Robert J. Freishtat (Washington DC, USA). 
 
4.4.3. Collection of nasal washes 
Nasal washes were performed by instilling 3 ml of sterile isotonic saline into each nare, 
holding for 10 s and then collecting in a specimen collection container. The withdrawal was 
centrifuged to remove the mucus and cellular debris. The remaining nasal wash supernatant 
was stored at -80°C until further use. The washes were performed and provided by the 
laboratory of Prof. Dr. Robert J. Freishtat (Washington DC, USA). 
 
4.5. RNA expression analysis 
4.5.1. Isolation of total RNAs including small RNA 
Prior to RNA isolation from murine lung tissue, the lungs were depleted from blood by trans-
cardial transfusion. Therefore, approximately 5 ml of PBS were injected in the right ventricle 
and blood loss was monitored via the color change in the tissue. The lung tissue was then 
Phenotype number ethnicity
sex 
(m/f)
age 
(years)
FEV1               
(% 
predicted)
serum 
IgE 
(U/ml)
blood 
eosinophils 
(%)
Allergic asthma n=7 black (4/3)
9.43      
± 1.51
83.14               
± 15.46
1095.14             
± 543.28
9.91 ± 4.20
Healthy controls n=10 caucasian (5/5)
9.11      
± 2.89
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dissociated in Qiazol reagent by a bead-based tissue homogenization using a MagnaLyser 
(Roche).  
For isolation of RNA from cell culture or exosomes, the Qiazol was directly added to the 
pellet and the samples were incubated for 5 min at room temperature and thoroughly 
vortexed. The isolation procedure was performed by using the miRNeasy Mini Kit (Qiagen) 
or the miRNeasy Micro Kit (Qiagen) for samples with low RNA amounts, like exosomes, 
according to the manufacture’s protocol. The concentration of RNA was determined by 
absorbance measurements (Nanodrop).  
 
4.5.2. Quality testing 
RNA quality was checked via agarose gel electrophoresis. Therefore, 1 µg of RNA was 
incubated with 5 µl formamide in a 10 µl reaction and denatured at 65°C for 15 min. 
Afterwards, the samples mixed with loading buffer containing SYBR green and separated in a 
1% agarose gel in TAE buffer at 65 V for 45 min. Afterwards, the gel was analyzed for the 
28S and 18S peaks of intact RNA with a Chemidoc XRS+ Imaging system. Only samples 
with satisfactory RNA quality were used for further analysis. 
 
4.5.3. Reverse-transcription quantitative real-time PCR 
4.5.3.1. Expression analysis of mRNA 
Expression levels of different genes were analyzed by qRT-PCR in a two-step procedure. 
First, the RNA was converted to cDNA with the Quantitect Reverse Transcription kit 
according to the manufacturer’s instructions. The remove residual genomic DNA 500 ng to 1 
µg of RNA per sample were incubated with gDNA wipe out buffer for 5 min at 42°C. 
Afterwards the master mix for the reverse transcription containing the enzyme, buffer and a 
random hexamer primer mix was added and incubated at 42°C for 30 min and 3 min at 95°C. 
The cDNA mix was diluted 1:10 prior to qPCR.  
Therefore, 2.5 µl of the specific cDNA was incubated with Light Cycler 480 SYBR Green I 
Master Mix and 3 pmol each of custom-designed primers (forward and reverse) for the gene 
of interest in a total volume of 10 µl in 96 well plates (primer sequences are listed under 
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MATERIALS section 3.4.). The thermal cycling conditions applied by the ROCHE LIGHT 
CYCLER 480 II platform were as follows:  
 
 
 
4.5.3.2. Expression analysis of miRNA 
For reverse transcription of miRNAs the TaqMan® reverse transcription kit was used 
according to the manufacturer’s instructions. Based on this technology, first a miRNA-
specific RT stem-loop primer (TaqMan® assay) is attached to the miRNAs and then they are 
converted to cDNA (112). Due to the high specificity of the miRNA primers, only 10 ng of 
total RNA were reversely transcribed for each sample and for each miRNA in separately. 
Thermal cycling conditions were 30 min at 16°C, 30 min at 42°C followed by 5 min at 85°C. 
Afterwards, the cDNA was diluted 1:1 prior to qPCR.  
For quantification, 2 µl of the specific cDNA was incubated with the miRNA-specific PCR 
primer (TaqMan® assay) and the TaqMan® Universal PCR master mix, NO AmpErase® 
UNG in a total volume of 10 µl in white 96 well plates. The reaction was performed using a 
ROCHE LIGHT CYCLER 480 II platform with the following thermal cycling conditions.  
 
 
 
Step Temperature Time
Pre-incubation 95°C 10:00
Amplification 95°C 0:10
60°C 0:15
72°C 0:10
78°C 0:01 Quantification, single
Melting Curve 95°C 0:05 continuous 5/°C
60°C 1:00
99°C -
Cooling 40°C 0:10
repeated for 50 
cycles
Temperature Time
Initial Denaturation 95°C 10 min
Denaturation 95°C 15s
Annealing/Extension 60°C 60s
Cool down 40°C ∞
repeated for 
50 cycles
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4.5.4. Normalization 
After the qPCR run, the data was processed and analyzed by the ROCHE LIGHT CYCLER 
software. For normal mRNA runs, the melting curves were evaluated to ensure generation of 
specific PCR products. The resulting Cp values were exported and used to calculate 
differences in expressions with the ∆∆Cp method with dCp=Cp(gene of interest)-Cp 
(reference gene). Hereby, HPRT was used as a stable reference gene for mRNA data 
normalization and the small nuclear RNAs RNU-6B (human) or sno-234 (mouse) for miRNA 
normalization. To normalize the expression of exosomal miRNAs, a defined amount (5.6 x 
106 copies/sample) of a C. elegans derived miRNA, called Ce-miR-39, was added during the 
miRNA isolation process. qPCR results were then normalized to the expression of this spike-
in control.  
 
4.6. Protein expression analysis 
4.6.1. Isolation of proteins 
In order to isolate proteins from lung tissue, approximately 1/4th of a lung lobe was manually 
dissected into small pieces by using a scalpel and then further homogenized (Polytron 
TP2100) in 300 µl RIPA buffer. Cells grown in adherent cultures were detached from the 
surface in RIPA buffer with cell scrapers and vortexed thoroughly for homogenization. The 
samples were incubated on ice for 45 min, vortexed every 10 min, followed by 2 times 
sonification (10 s, 5 cycles, power 20%). Cell debris was removed by a 10 min centrifugation 
at 10,000g at 4°C and the proteins were stored at -20°C until further analysis or -80°C for 
long term storage.  
 
4.6.2. Measurement of protein concentration 
The protein samples were measured with a BCA protein assay kit according to the 
manufacturer’s recommendations and analyzed with a fluorescence plate reader (Tecan 
Sunrise) at wavelength 595 nm. Concentrations were calculated by referring absorbance 
values to a linear BSA protein standard (concentrations 2 – 0.00097 mg/ml) on the same plate.  
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4.6.3. Western blot 
For detection of specific proteins, they were firstly separated by size with an SDS gel 
electrophoresis. Therefore, 20 µg of each protein lysate was mixed with 6x Laemmli loading 
dye and RIPA buffer to an equal volume and applied into single lanes in a 20% 
polyacrylamide gel. Electrophoresis was performed in Tris-based running buffer with SDS for 
120 min at 100 V. Afterwards, proteins were transferred to PVDF membranes for 90 min at 
4°C by a standard wet blotting procedure in transfer buffer without SDS. The membranes 
were blocked in TBST containing 5% bovine serum albumin (BSA) for one hour at room 
temperature and then incubated under constant agitation over night at 4°C with antibodies 
against CREB1, CRTC1, CRTC3, SEC14L3 or GAPDH (all 1:1000 in 5% BSA in TBS-T). 
After washing, the membranes three times with TBST for 10 min at room temperature and 
constant agitation, they were incubated 1.5 h at room temperature with secondary HRP-
conjugated goat anti-rabbit IgG antibody (1:40000, 5% BSA in TBS-T). The secondary 
antibody was removed by three 10 min washing steps in TBS-T. Prior to development the 
HRP substrates ECL, Dura-ECL or Femto-ECL were applied to the membrane, incubated for 
5 min and the chemiluminescent signal was recorded with a Chemidoc XRS+ imaging 
system. For reprobing with new antibodies, membranes were incubated for 5 min at room 
temperature in RestorePlus® stripping buffer, washed three times with TBST and then 
blocked in 5% BSA for 1 h. Quantification of band intensities was performed with the Image 
Lab software v4.01 and normalized to the intensity of the loading control (GAPDH).  
 
4.6.4. Immunofluorescence 
Sec14l3 expression in murine lung tissues was determined by immunofluorescence using a 
specific Sec14l3 antibody. After removal of paraffin and rehydration of the tissue (see 4.2.) 
antigens were demasked by treatment of sections with citrate buffer (pH 6) at 125°C for 30 s 
and at 90°C for 10 s. After washing the sections three times in Na-Tris buffer, endogenous 
peroxidises were blocked for 15 min by an aqueous H2O2 solution. The sections were again 
washed three times with Na-Tris buffer, air-dried and then incubated with primary antibody 
(rabbit anti-Sec14l3; 1:200 in 100 µl antibody diluent) for 1 h at room temperature. After 
three washing steps with Na-Tris buffer, the secondary antibody Alexa Fluor 568 goat anti-
rabbit IgG (H+L) (1:250 in 100 µl) was added onto the slides and left for 30 min at room 
temperature in the dark. Slides were washed three times with Na-Tris buffer and nuclei were 
co-stained with DAPI (1:2500, 0.5 µg DAPI/ml) for 1 min at room temperature. Finally, the 
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sections were washed again and then covered with fluorescence mounting medium and a 
cover slide. The slides were stored in the dark at 4°C.  
If the identical sections were used for a subsequent PAS staining they were incubated 
overnight in Na-Tris buffer to remove the water soluble mounting medium and the cover 
slide. Afterwards, the slides were washed in ddH2O to remove salt residues and stained as 
described in 4.2.  
 
4.7. Isolation and analysis of exosomes 
4.7.1. Isolation of exosomes 
Exosomes were isolated from body fluids or cell culture medium by precipitation with 
ExoQuick-TC reagent according to the manufacturer’s instructions. Briefly, cell debris was 
removed by a 10 min centrifugation at 3000 g, then 1/5th volume of ExoQuick-TC was added 
to the supernatant and incubated over night at 4°C. The exosomes were spun down at 1500 g 
for 30 min and the exosome pellet was resuspended in either 200 µl exosome binding buffer 
for quantification by ELISA, 200 µl PBS for flow cytometry analysis or 700 µl of Qiazol 
reagent for miRNA isolation.  
 
4.7.2. Quantification by CD63 ELISA 
The exosomes collected from the supernatants of the primary NHBE culture were quantified 
by a specific CD63 ELISA kit according to the manufacturer’s recommendation. Briefly, the 
exosome pellet after the precipitation with Exoquick-TC was resuspended in 200 µl exosome 
binding buffer, vortexed, incubated for 20 min at 37°C and centrifuged for 5 min at 1500 g. 
The supernatant containing the liberated exosome proteins was then added to a 96 well plate 
in duplicates, together with defined amounts of an exosomal standard (range from 1.35 x 1010 
to 2.1 x 108 exosomes) and then incubated overnight at 37°C to enable binding of the 
exosomes to the microplate. The next day, the plate content was emptied by inversion and 
hard tapping it on a paper towel and washed three times for 5 min with 100 µl of wash buffer 
per well under constant agitation. Next, the primary antibody against CD63 was diluted 1:100 
in blocking buffer and 50 µl of the respective solution was added to each well and incubated 
for 1 h at room temperature with shaking. After three further 5 min washing steps, the HRP-
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coupled secondary antibody (1:5000 in blocking buffer) was incubated in 50 µl per well for 1 
h at room temperature and shaking. Residual antibody was washed away three times for 5 min 
and the plate was developed by addition of 50 µl TMB ELISA substrate per well and shaking 
for 15 min at room temperature. The substrate reaction was stopped with 50 µl of Stop buffer, 
which changed the color from blue to yellow. The plate was subsequently analyzed with a 
plate reader at 450 nm wavelength.  
 
4.7.3. Quantification by flow cytometry 
Exosomes are too small to be analyzed by regular flow cytometry techniques, thus the use of 
latex beads coated with an antibody against the common exosomal protein CD63 was 
necessary.  
Therefore, 4µm latex beads were washed twice with MES buffer for 15-20 min at 1500 g and 
then coated with a CD63 antibody (1:20 in MES buffer) overnight under constant agitation at 
room temperature. The next day, the beads were washed three times for 20 min each at 1500 g 
with PBS and afterwards resuspended in 100 µl of MES buffer. Meanwhile, the exosomes 
were labeled with PKH-67, a green fluorescent membrane dye that binds to lipid regions of 
cells or vesicles due to its long aliphatic tail. The exosomes were resuspended in 500 µl of 
diluent C and 4 µl of the PKH dye were added to a separate tube with 500 µl of diluent C to 
obtain the PKH working solution. Both, the PKH working solution and the exosome solution 
were combined in one tube and incubated for 5 min at room temperature. The labeling was 
stopped by adding 1 ml of exosome-depleted FCS to the tube. After a 5 min incubation, the 
labeled exosomes were added to the antibody-coated beads and kept overnight at 4°C under 
constant agitation. The exosome-bead complexes were washed twice in PBS containing 1% 
exosome-depleted FCS at 800 g for 10 min and then resuspended in 500 µl of flow cytometry 
buffer. The fluorescence was analysed in the FITC channel on the LSRII flow cytometer. For 
quantification the sample fluorescence was compared to a standard curve of six defined 
amounts of purchased exosome standards (derived from a colon carcinoma cell line) in a 
concentration range from 12-0 µg/ml that were processed the same way as the samples. 
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4.7.4. Microscopy uptake studies of exosomes to target cells 
For visual assessment of the exosome uptake to different cell lines by microscopy, the 
exosomes were labeled with PKH-67 as described in 4.7.3. The labeled exosomes were then 
incubated with different cell types in 48 well plates. After 24 h the cells were washed with 
PBS and spun on a glass slide with a cytospin centrifuge (10 min, 300 g). The slides were air-
dried overnight and then the nuclei were stained with DAPI as in 4.6.4. 
 
4.8. In silico research 
4.8.1. miRNA target prediction 
miRNA bind to the 3’UTR of their target genes with their 2-8 nucleotide long seed sequence. 
In this study, the 3’UTR of the Creb1 co-activators Crtc-1, -2 and -3 were screened for 
binding sites of the candidate miRNAs miR-17, miR-144 and miR-21 by using the free 
available algorithm TargetScan (www.targetscan.org).  
 
4.8.2. Identification of asthma-relevant putative Creb1 target genes 
The transcription factor Creb and its co-activators bind to palindromic CRE sites in the 
promoter region of their target genes to initiate transcription. In order to identify Creb 
downstream targets relevant for the pathogenesis of experimental asthma, a dataset from a 
previously performed microarray (courtesy of Francesca Alessandrini, ZAUM Munich) of 
lung homogenate of OVA-treated animals vs. PBS-treated controls was used. As the 
transcription factor Creb1 was found to be down-regulated in experimental asthma, only 
genes down-regulated in experimental asthma were screened for CRE sites in their promoter 
region by using the MatInspector Release professional 8.0.5 software. The identification of 
CRE sites and analysis of the conservation throughout different species was performed by 
Andreas Kowarsch and Steffen Sass (MIPS, Munich).  
 
4.9. Statistical analysis 
The acquired data was analyzed with the GraphPad Prism (Version 5.04) software. The 
graphs represent mean ± SD. Statistical significance is assumed if p ≤ 0.05. All experiments 
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were analyzed with the non-parametric Mann-Whitney U test, unless stated otherwise in the 
figure legends. Each experiment was performed at least three independent times and the exact 
number is stated in the figure legends.  
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5. RESULTS 
5.1. Characterization of animal models for allergic airway inflammation 
In order to investigate molecular pathways of relevance for asthma, we artificially induced 
allergic airway inflammation (AAI) in mice by several sensitization steps and challenges with 
two different allergens: ovalbumin and house-dust mite.  
 
5.1.1. Ovalbumin model 
5.1.1.1. Inflammatory cell counts in broncho-alveolar lavage (BAL) 
For validating the induced allergic inflammation in the airways, we first assessed the 
inflammatory cell numbers in the BAL of the mice.  
 
 
Figure 5.1: Increased inflammatory cell counts in BAL of OVA-induced allergic airway inflammation. A, Total cell 
count in BAL. B, Differential cell counts of cytospins of PBS/OVA, OVA/PBS and OVA/OVA treated mice,  n = 7-15 per 
group. *p<0.05, ***p<0.001 vs. PBS/OVA. Courtesy of Dr. Nikola Schulz (104). 
 
The total BAL cell number was significantly increased in OVA/OVA treated animals but not 
in animals that were only challenged (PBS/OVA) (Fig. 5.1A). The differential cell counts 
revealed a significant increase in neutrophils, eosinophils and lymphocytes in animals with 
OVA-induced allergic inflammation compared to the controls (Fig. 5.1B). This data was 
generated and provided by Dr. Nikola Schulz (104). 
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5.1.1.2. Histology 
Histological analysis of lung sections showed some cellular infiltrates (Fig. 5.2) around the 
major airways and blood vessels, as well as a pink staining for mucus producing cells in the 
bronchi, suggesting goblet cell metaplasia in the OVA/OVA animals. This effect was not seen 
in PBS/OVA control animals. 
 
 
Figure 5.2: OVA/OVA treatment induces inflammatory cell infiltrates and goblet cell metaplasia. PAS staining of lung 
tissue of PBS/OVA (upper panel) and OVA/OVA (lower panel) treated mice. Representative images of n=4 mice per group 
are shown. Left panel 5x objective, right panel 63x objective. 
 
Taken together, the data suggests that the applied ovalbumin treatment results in a moderate 
AAI in mice. This model has been performed by Francesca Alessandrini, ZAUM Munich, and 
is already described in the PhD thesis of Dr. Nikola Schulz (104).  
 
5.1.2. House dust mite model 
Next, we aimed to validate our findings in a second murine model that is more relevant to 
human asthma. Therefore, we used the model of house dust mite (HDM) induced allergic 
airway inflammation.   
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5.1.2.1. Inflammatory cell counts in broncho-alveolar lavage 
HDM-treated mice showed significantly higher total cell counts in BAL (Fig. 5.3A) and also 
higher numbers of macrophages, eosinophils, neutrophils and lymphocytes (Fig. 5.3B) 
compared to PBS treated controls. 
 
 
Figure 5.3: Increased inflammatory cell counts in BAL of HDM-treated mice. A, Total cell count in BAL. B, Differential 
cell counts of cytospins of PBS vs. HDM-treated mice, n = 12 per group. ***p<0.001 vs. PBS 
 
5.1.2.2. Histology 
PAS staining of lung sections demonstrated a moderate goblet cell metaplasia with pink 
staining for mucus-producing cells in major airways, as well as immune cell infiltrates around 
blood vessels and airways (Fig. 5.4).  
 
Figure 5.4: HDM-treatment induces airway inflammation and goblet cell metaplasia. PAS staining of PBS (upper panel) 
and HDM (lower panel) treated mice. Representative images of n=4 mice per group are shown. Left panel 5x objective, right 
panel 63x objective. 
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5.1.2.3. Airway hyperreactivity after metacholine challenge 
In order to investigate if the animals display airway hyperreactivity (AHR), HDM or PBS-
treated mice were tracheotomised and subjected to increasing doses of the broncho-constrictor 
metacholine. As shown in Figure 5.5, animals treated with HDM extract showed significantly 
higher airway resistance after metacholine challenge than PBS-treated control animals.   
 
Figure 5.5: HDM-treated mice show increased airway hyperreactivity in response to metacholine. Airway resistance 
(RI av.) after metacholine challenge, n=12/group, ***p<0.001 vs. PBS. 
 
In summary, HDM-treated mice displayed the expected symptoms of experimental allergic 
airway inflammation such as inflammatory cell infiltrates, goblet cell metaplasia and 
increased AHR in response to metacholine. The HDM-induced AAI was more severe with 
regards to airway inflammation than the phenotype observed in the ovalbumin model. 
Treatments and analysis were performed together with Petra Nathan, Katrin Milger and 
Jeremias Götschke (CPC Munich). 
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5.2. Identification of Creb1 co-activators as targets for candidate miRNAs 
5.2.1. In silico research for miRNA binding sites in the Creb1 pathway 
MiRNAs tend to address several molecules along single signaling pathways (62–64). Thus, a 
joint down-regulation of several factors along one pathway could lead to more profound 
downstream effects. Therefore, we screened the 3’UTRs of the Creb1 co-activators Crtc-1, -2 
and -3 for binding sites of miR-17 and miR-144 that also target Creb1. In silico research 
identified miR-17 and -144 binding sites in the 3’-UTRs of Crtc-1, -2 and -3 in mice and 
human, whereas miR-17 binding sites were only present in the human CRTCs (Table 5.1). 
miR-21 was newly included as it was the second highest “hit” in the initial array used for the 
target prediction (adj. p-value 6.18 x 10-13) and was predicted to target CRTC-1, -3 and 
CREB1.  
 
Table 5.1: predicted miRNA binding sites 
 
 
5.2.2. Over-expression of miR-17/-144 and -21 in MLE-12 cells 
In silico target predictions can produce false negative hits. Therefore, we aimed to validate the 
miRNA-dependent regulation of Creb1 and the Crtcs by evaluating the effect of in vitro 
miRNA over-expressions on the endogeneous expression of the putative target genes.  
In vitro, miR-144 and miR-21 over-expression reduced significantly the mRNA levels of all 
three Crtcs in a murine bronchial epithelial cell line (MLE-12) (Fig. 5.6A). PremiR-17 
decreased Crtc2 mRNA levels and Creb1 and trendwise Crtc1 and -3 protein levels (Figure 
5.6A, B). The Creb1 protein levels were also significantly decreased after PremiR-144 
treatment (Fig.5.6B). 
miRNA
Crtc1    
mmu (hsa)
Crtc2    
mmu (hsa)
Crtc3    
mmu (hsa)
Creb1    
mmu (hsa)
Sec14l3       
mmu (hsa)
miR-17   - (+)  - (-)   - (+)   + (+)  - (-)
miR-144  + (+)  + (-)  + (+)  + (+)  - (+)
miR-21  + (+)  - (-)  - (+)  + (+)  - (-)
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Figure 5.6: miRNA-mediated regulation of Crtcs in vitro. Transfection of MLE-12 cells with PremiRs vs. a scrambled 
miRNA control for 72 h. A, qRT-PCR for Crtc1,-2 and -3 and B, representative western blot (different transfection 
conditions are depicted as duplicates) and densitometrical analysis, n=4-5 independent experiments. *p<0.05, **p<0.01 vs. 
scrambled control. 
 
In summary the data suggests that miR-17, miR-144, and miR-21 might play a role in the 
regulation of Creb/Crtc-mediated signaling in murine cells.  
 
5.3. Down-regulation of Creb1 and Crtcs in murine experimental asthma 
5.3.1. Creb1 and Crtc mRNA and protein expression in OVA-induced AAI 
In a next step, we wanted to investigate if Creb1 and its co-activators are involved in the 
pathogenesis of asthma. Therefore, we evaluated their expression in lung homogenates of 
animals with OVA-induced AAI.  
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There was a significant increase in miR-17, -144, and -21 (Fig. 5.7A) in lung homogenates of 
OVA-treated animals compared to PBS-treated controls after the allergen challenge at day 72, 
but not at day 29 within the sensitization period (104). At day 72, Creb1 and trendwise Crtc1 
(p=0.095) were decreased on mRNA level compared to PBS-treated controls (Fig. 5.7B). The 
total transcript levels of Creb1 and all three Crtcs decreased in lung homogenate of mice that 
developed AAI along the treatment protocol from day 29 to day 72 (Fig. 5.7B).  
 
 
Figure 5.7: Inverse correlation between miRNA and Creb1/Crtc expression in OVA-induced allergic airway 
inflammation. A, qRT-PCR for miRNA on lung homogenates at d29 and d72. Already published in the PHD Thesis of Dr. 
Nikola Schulz (104) .B, qRT-PCR for Creb1 and Crtcs at d29 and d72. Graphs depict fold change to PBS/OVA controls, n=5 
animals per group, dCp=Cp(gene of interest)-Cp (reference gene). *p<0.05, **p<0.01 vs. PBS.  
 
On protein level, Crtc1 and Crtc3 increased from d29 to d72 in control mice. This increase 
was significantly attenuated for Crtc3 and trendwise for Crtc1 (p=0.095) in mice that 
developed allergic airway inflammation (Figure 5.8). 
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Figure 5.8: Crtc3 protein levels decrease in OVA/OVA-treated animals. Western blots of lung homogenates of n=5 mice 
from d29 to d72. Crtc2 cannot be assessed due to the lack of a specific antibody. **p<0.01 vs. d29. 
 
Creb1 mRNA is decreased in OVA-induced AAI, its co-activators show only a small trend 
after the challenge but are decreased by a continuous OVA treatment along the treatment 
protocol.  
 
5.3.2. Creb1 and Crtc mRNA and protein expression in HDM-induced AAI 
As the ovalbumin-model has limited relevance for human asthma, we further wanted to 
validate our findings in HDM-induced experimental allergic airway inflammation. Creb1 and 
all three Crtc mRNA levels were highly significantly decreased in HDM-treated animals (Fig. 
5.9A). HDM-treatment also significantly reduced Crtc3 and trendwise Creb1 protein levels 
(Figure 5.9B). This regulation was more pronounced than in the OVA model. 
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Figure 5.9: Creb1 and Crtcs are decreased in HDM-induced experimental asthma. Expression analysis of lung 
homogenates of HDM-treated mice vs. PBS-treated controls. A, qRT-PCR for Creb1 and Crtc1-3 B, Densitometrical analysis 
of Creb1 and Crtc-1 and -3 of a western blot (n=6 mice per group), dCp=Cp(gene of interest)-Cp (reference gene). *p<0.05, 
**p<0.01 vs. PBS. 
 
In summary, we could observe a trend towards a decrease of the putative targets of miR-17, -
144, and -21 Creb1 and Crtc1-3 in the OVA-model for AAI. This could be validated with 
more pronounced regulations in HDM-induced AAI.  
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5.4. Identification of relevant Creb1 target genes in experimental asthma 
5.4.1. Prioritization strategy 
As our data suggested Creb1 and Crtcs to be important for the development of experimental 
asthma, we asked whether their down-regulation also results in a decreased transcription of 
Creb1 target genes. To this end, we searched an earlier performed mRNA array (113) (GEO 
database, ID: GSE6496 (http://www.ncbi.nlm.nih.gov/geo) (Courtesy of Francesca 
Alessandrini, ZAUM Munich) for down-regulated genes containing CRE-sites in OVA/OVA 
versus PBS/OVA mice. Of 185 decreased genes, 35 contained CRE-elements (Table 5.2). In a 
pilot approach, we selected Sec14-like 3 (Sec14l3) for further investigation as it had already 
been found to be decreased in allergic airway inflammation in rats (114) and to be specifically 
expressed in murine airway ciliated cells (115). 
 
Table 5.2: Dysregulated putative Creb1 target genes in OVA-induced asthma 
 
 
Gene symbol GeneID
logFC                     
(OVA/OVA vs 
PBS/OVA)
Dcpp1 13184 -2.69
Tnnt3 21957 -2.30
Tnni2 21953 -1.89
Ddx5 13207 -1.84
Tnnc2 21925 -1.80
Car3 12350 -1.77
Lor 16939 -1.71
Ghitm 66092 -1.69
Calml3 70405 -1.62
Sec14l3 380683 -1.34
Gpd1 14555 -1.29
Tubb2c 227613 -1.21
Rbbp7 245688 -1.20
Caprin1 53872 -1.17
Son 20658 -1.17
Ddx17 67040 -1.15
Cap2 67252 -1.13
Mgll 23945 -1.09
Mapk3 26417 -1.07
Ltbp4 108075 -1.05
Ppp1cb 19046 -1.05
Rsrc2 208606 -1.04
Tap1 21354 -1.02
Akap3 11642 -1.02
Tcp1 21454 -1.01
Krt14 16664 -1.00
Nup155 170762 -0.95
Dnajb6 23950 -0.94
Mark3 17169 -0.91
Cask 12361 -0.89
Lypd3 72434 -0.89
Cidea 12683 -0.86
Sypl 19027 -0.86
Atp8a1 11980 -0.84
Fabp5 16592 -0.83
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5.4.2. Expression Sec14l3 in OVA-induced AAI 
The putative Creb1 target gene Sec14l3 was significantly decreased at d72, but not at d29 
within the sensitization period, at the mRNA level in lung homogenate of OVA/OVA animals 
compared to PBS/OVA controls (Fig. 5.10A). The Sec14l3 protein increased from d29 to d72, 
like observed for Crtc-1 and -3, and this was significantly attenuated in OVA-induced allergic 
airway inflammation (Fig. 5.10B). 
 
 
Figure 5.10: Sec14l3 is decreased in OVA-induced allergic airway inflammation. Lung homogenates of OVA/OVA-
treated animals vs. PBS/OVA-treated controls. A, qRT-PCR for Sec14l3. B, Western blot of animals on d29 and d72 and 
respective densitometrical analysis (n=5 mice per group). dCp=Cp(gene of interest)-Cp (reference gene). **p<0.01 vs. 
PBS/OVA or d29.  
 
According to published data, Sec14l3 is specifically expressed in airway ciliated cells in 
murine lungs (115). To further investigate its expression in OVA-induced allergic airway 
inflammation we performed specific immunofluorescent stainings on lung sections. Indeed, 
Sec14l3 was expressed in ciliated bronchial epithelial cells and this was decreased in allergic 
airway inflammation (Fig. 5.11). Where the Sec14l3+ cells were lost in OVA-treated animals 
(lower panel, arrows), a goblet cell could be identified by subsequent PAS staining of the 
identical sections (Fig. 5.11). Hence, the loss of Sec14l3 expression may be associated with 
goblet cell metaplasia, a common hallmark for allergic airway disease.  
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Figure 5.11: Sec14l3 is expressed in airway ciliated cells and decreased in OVA-induced allergic airway inflammation. 
Left panel: Immunofluorescent staining of paraffin lung sections of PBS/OVA (upper panel) and OVA/OVA mice (lower 
panel): Sec14l3 (red) vs. DAPI (blue) and lung autofluorescence (green). Right panel: PAS staining of the identical lung 
sections. Arrows indicate ciliated cells in the upper panel and goblet cells in the lower panel. Representative images for n=4 
mice per group. 
 
5.4.3. Expression of Sec14l3 in HDM-induced AAI 
Sec14l3 was found to be decreased on mRNA (Fig. 5.15A) as well as protein level in lung 
homogenate of HDM treated mice compared to the healthy controls (Fig. 5.12B).  
 
Figure 5.12: Sec14l3 is decreased in HDM-induced allergic airway inflammation. Lung homogenate of HDM-treated 
mice vs. PBS-treated mice. A, qRT-PCR for Sec14l3. B, Densitometrical analysis of western blot. (n=6 mice per group), 
*p<0.05, **p<0.01 vs. PBS. 
 
Furthermore we observed the same association with goblet cell metaplasia than in the 
ovalbumin model (5.4.2) (Fig. 5.13). 
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Figure 5.13: Sec14l3 is expressed in airway ciliated cells and decreased in HDM-induced allergic airway 
inflammation. Left panel: Immunofluorescent staining of paraffin lung sections of PBS (upper panel) and HDM mice (lower 
panel): Sec14l3 (red) vs. DAPI (blue) and lung autofluorescence (green). Right panel: PAS staining of the identical lung 
sections. Arrows indicate ciliated cells in the upper panel and goblet cells in the lower panel. Representative images for n=4 
mice per group. 
 
Thus, the putative Creb1 target gene Sec14l3 was, similar to Creb1 and co-activators, down-
regulated in lung homogenates of both murine models for allergic airway inflammation, thus 
independent of the type of allergen. Additionally, the Sec14l3 loss seemed to be associated 
with goblet cell metaplasia.  
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5.5. Investigation of the miRNA/CREB1/SEC14L3 axis in air-liquid interface 
differentiation of primary NHBE 
So far, we used murine lung homogenates to investigate the expression of miRNAs and the 
Creb1/Crtc pathway. However, current concepts propose that the bronchial epithelium may 
contribute actively to the pathogenesis of asthma. Therefore, we used primary normal human 
bronchial epithelial cells (NHBE) to investigate the role of SEC14L3 in the development of 
experimental asthma and in normal lung homeostasis. Those cells, when cultured on transwell 
inserts at the air-liquid interface, differentiate into a pseudo-stratified epithelium containing 
ciliated cells, club cells, goblet cells and basal cells over a period of 21-28 days (116).  
 
5.5.1. Timeline of normal differentiation  
First we assessed the expression of Sec14l3 during the 28 days of differentiation of primary 
NHBE cells at the air-liquid interface.  
On day 0, the day of air-lift, SEC14L3 mRNA could not be detected, but it increased 
continuously until day 28 (Fig. 5.14A). We found a very close correlation of SEC14L3 mRNA 
level with the expression of the transcription factor forkhead box protein J1 (FOXJ1) that is 
associated with the development and function of ciliated cells (117) (Fig. 5.14B).  
 
 
Figure 5.14: SEC14l3 mRNA correlates with ciliated cells in NHBE cells. NHBE cells were differentiated at the air-liquid 
interface for 28 days. Left panel: qRT-PCR for SEC14L3 and FOXJ1. Right panel: Linear correlation of SEC14L3 and 
FOXJ1 mRNA levels. n=4 independent experiments. 
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5.5.2. Treatment of primary NHBE cells with IL-13 
5.5.2.1. Induction of goblet cell metaplasia  
The NHBE cells were treated with IL-13 for seven days in basal medium to induce a goblet 
cell metaplasia (118) and to model the initial development of “asthma-like” changes in the 
bronchial epithelium.  
Samples were taken at 24 hours, four days and seven days after air-lift (d0) to get an insight 
into the dynamic changes induced by the cytokine treatment. PAS stainings of the cross-
section transwell membranes showed an increased mucus production of the IL-13-treated cells 
(displays as pink color) compared to the untreated controls. This was especially visible after 7 
d of culture (Fig. 5.15A). A prominent marker for mucus-producing goblet cells, mucin 5AC 
(MUC5AC) (119), also significantly increased at mRNA level over the treatment period (Fig. 
E.15B). 
 
 
Figure 5.15: IL-13 induces goblet cell metaplasia and mucus production in NHBE cells. NHBE cells were treated with 
10ng/ml IL-13 for 7d. A, Representative PAS-stainings of cross sections of the transwell membranes of untreated cells (upper 
panel) vs. IL-13 treated cells (lower panel) at 24 h, 4 d and 7 d post airlift. B, qRT-PCR of MUC5AC. n=4 independent 
experiments, *p<0.05 vs. untreated. 
 
5.5.2.2. Expression of miRNAs  
The expression of the three candidate miRNAs in the primary NHBE cells did not 
significantly change after treatment with IL-13. There might be a trendwise increase for miR-
144 and miR-21 after 7 days of treatment (Fig. 5.16) although this did not reach statistical 
significance. 
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Figure 5.16: miRNA expression in NHBE cells after IL-13 treatment. qRT-PCR for miR-17, -144 and -21 in NHBE cells 
at 24 h, 4 d and 7 d post air-lift. 
 
5.5.2.3. Secretion of miRNAs in exosomes  
As we did not observe changes in miRNA levels in the total cell lysates, we asked if they 
might be secreted into exosomes upon IL-13 stimulus. We could detect CD63 positive 
exosomes by ELISA in the basal compartment of our culture model as well as in washes of 
the apical side (Fig. 5.17A). We could not observe an enhanced secretion of exosomes after 
IL-13 treatment to either apical or basal cell compartments but the basal compartment 
contained per se more exosomes than the apical at every time point (Fig. 5.17B).  
 
 
Figure 5.17: Exosomes are secreted apically and basally after IL-13 treatment in NHBEs. ELISA for exosome-specific 
CD63 from (A) apical and basal compartments of NHBE cells after IL-13 or control treatment. B, comparison of CD63-
positive exosomes between apical and basal compartments in untreated cells. Amounts were calculated by an internal 
standard curve with defined amount of exosomes. n=3 independent exosome isolations. *p<0.05 vs. apical exosomes 
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In our culture model, we could isolate miRNAs from exosomes of the apical, as well as the 
basal side. In untreated cells, the total levels of miR-17 and trendwise miR-21 were higher in 
the basal compartment, especially after 7 days of culture (Fig. 5.18). This might relate to the 
higher amount of exosomes that are present in the basal compartment (Fig. 5.17B). However 
we could not observe this pattern for miR-144 (Fig. 5.18).  
 
Figure 5.18: miRNAs are present in exosomes secreted by primary NHBE cells. qRT-PCR for miR-17, -144 & -21 in 
isolated exosomes from the apical and basal cell side after 24 h, four days and seven days of culture without treatment. 
*p<0.05 vs. apical exosomes. 
 
Of note, there were significantly higher amounts of miR-17 and -21 in the basal compartment 
after 24 hours and 4 days of IL-13-treatment (Fig. 5.19A). After seven days this significant 
increase in the miRNAs was observed on the apical side, suggesting that IL-13 affects the 
direction of miRNA secretion in a temporal manner (Fig. 5.19B). This might indicate either 
an altered secretion mechansism upon continuous IL-13 treatment or a diffusion from basal 
exosomes to the apical side through openend tight junctions. MiR-144 only showed a 
trendwise increase in either apical or basal compartment (Fig. 5.19A, B) but it did not reach 
statistical significance. Eventhough the number of exosomes was always higher in the basal 
compartment than in the apical, the pattern of the miRNA levels was not so clear. This could 
indicate a specific packing of miRNAs into exosomes depending on the stimulus.  
 
 
Figure 5.19: miRNAs are secreted into exosomes after IL-13 treatment by primary NHBE cells. qRT-PCR for miR-17, -
144 & -21 in isolated exosomes from the apical (left panel) and basal (right panel) cell side. *p<0.05 vs. untreated. 
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5.5.2.4. CREB/CRTC-mediated transcription 
Regarding CREB1 and its co-activators CRTC we could observe a significant decrease 24 h 
after the IL-13 treatment start on the transcriptional level, which then resolved over time (Fig. 
5.20A). SEC14l3 and FOXJ1 transcripts could not be detected after 24 hours but where 
significantly lower in the IL-13 treated cells at four and seven days compared to the non-
treated controls. The treatment abolished the increase we observed during the normal 
differentiation (Fig. 5.20B).  
 
 
Figure 5.20: CREB1/CRTCs and SEC14L3 are dysregulated by IL-13 treatment in primary NHBE cells. qRT-PCR for 
CREB1, CRTC1-3 (A) and SEC14L3 and FOXJ1 (B) in IL-13 treated NHBE cells vs. untreated controls. n.d. = non 
detectable. *p<0.05 vs. untreated. 
 
Our findings were largely mirrored on the protein levels, although the decrease of CREB1 and 
CRTCs was first visible after 4 days and 7 days (Fig. 5.21). FOXJ1 down-regulation was less 
profound than on mRNA level.  
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Figure 5.21: CREB1/CRTC and FOXJ1 protein levels are decreased by IL-13 treatment in primary NHBE cells. Left 
panel: Western blot of IL-13 treated cells vs. untreated control cells. Right panel: Densitometrical analysis of n=4 
independent experiments. *p<0.05 vs. untreated. 
 
In summary, a decreased CREB1/CRTC-mediated transcription of possibly SEC14L3 and 
others might be involved in early changes in the bronchial epithelium after “asthmatic 
stimuli”.  
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5.6. Investigation of the miRNA/CREB1/SEC14L3 axis in human paediatric 
asthma 
Next, we wanted to investigate to what extent the results obtained in vitro and in mouse 
models translate to human paediatric asthma. To this end, we analyzed the expression of the 
miRNA/CREB1/SEC14L3 axis in nasal epithelial cells from children with allergic asthma 
compared to healthy controls.  
 
5.6.1. miRNA expression in nasal epithelial cells 
We first compared the expression of miRNAs in the nasal epithelial cells of children with 
allergic asthma and healthy controls. miR-17, miR-144 and miR-21 were significantly up-
regulated in children with allergic asthma: miR-144 in particular was expressed at very low 
baseline levels in healthy controls but increased to a high level in most children with allergic 
asthma (Fig. 5.22).  
 
 
Figure 5.22: miR-17, -144 and -21 are increased in children with allergic asthma. qRT-PCR of nasal epithelial cells from 
children with allergic asthma (n=7) vs. age-matched healthy controls (n=10). dCp=Cp(gene of interest)-Cp (reference gene). 
*p<0.05, **p<0.001vs. control.  
 
5.6.2. CREB1/CRTC and SEC14L3 mRNA expression 
The mRNA levels of CREB1 and the three CRTCs were not changed between children with 
allergic asthma and healthy controls (Fig. 5.23).  
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Figure 5.23: CREB1 and CRTCs are unchanged in paediatric allergic asthma. qRT-PCR of nasal epithelial cells from 
children with allergic asthma (n=7) vs. age-matched healthy controls (n=10). 
 
Nonetheless, SEC14L3 was markedly and significantly decreased in children with allergic 
asthma (mean fold change to control: 0.13±0.05; p=0.0007) (Fig. 5.24A) and this 
dysregulation was more pronounced than what we had observed in the murine models. In 
experimental asthma, loss of SEC14L3 was associated with goblet cell metaplasia. Hence we 
investigated the expression MUC5AC as surrogate marker for goblet cells (119) and found it 
to be increased in nasal epithelial cells of asthmatic children (Fig. 5.24B).  
 
 
Figure 5.24: SEC14L3 is decreased in children with allergic asthma. qRT-PCR of nasal epithelial cells from children with 
allergic asthma (n=7) vs. age-matched healthy controls (n=10). Left panel: SEC14l3. Right panel: MUC5AC. dCp=Cp(gene 
of interest)-Cp (reference gene) *p<0.05, ***p<0.001 vs. control.  
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5.6.3. Presence of miRNA containing exosomes in nasal washes and murine 
BAL fluid 
As the primary NHBE cells secreted miRNAs into exosomes, we investigated biofluids of the 
OVA-mouse model and the asthmatic children for the presence of miRNA-containing 
exosomes. We did not observe a significant increase in CD63+ exosomes in BALF of OVA-
treated mice (Fig. 5.25A). Nonetheless, miR-17, and -21 were significantly increased 
compared to PBS/OVA treated controls, while miR-144 was not detectable (Fig. 5.25B).  
 
Figure 5.25: miRNAs are present in exosomes in murine BALF. A, quantification of CD63+ exosomes by flow 
cytometry, isolated of 200 µl of murine BALF. B, qRT-PCR on isolated exosomes of murine BALF, miR-144 not detectable. 
N=3 mice/group. Unpaired ttest **p<0.01 vs. PBS/OVA.  
 
In exosomes isolated from human nasal washes, we were able to detect all three miRNAs by 
qRT-PCR, although miR-144 only at very low levels (Fig. E.26A). As we did not have access 
to nasal washes from healthy control children, we could not validate the observed increase in 
exosomal miRNAs that we found in the mouse model for allergic airway inflammation. 
 In order to get an insight if the presence of exosomal miRNAs is dependent on clinical 
parameters of asthma or allergic disease, we stratified our patients in two groups of children 
with lower IgE levels (still elevated compared to normal levels) and higher IgE levels. miR-17 
was significantly higher and miR-21 also trendwise (p=0.08) in patients with high IgE levels 
compared to patients with lower levels of IgE (Fig. 5.26B). We could not observe such an 
increase for miR-144. The increased miRNA levels might in part be explained by a higher 
amount of CD63+ exosomes in human nasal washes from patients with higher IgE levels (Fig. 
5.26C).  
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Figure 5.26: miRNAs are present in exosomes in human nasal washes. A, qRT-PCR on isolated exosomes of 1ml of 
human paediatric nasal washes of 11 children with allergic asthma. B, Patients were stratified in ‘low’ IgE levels in blood 
(400-900 U/ml) and ‘high’ IgE levels in blood (900-4500 U/ml). Graph depicts qRT-PCR for miR-17, -21 and -144. C, 
quantification of CD63+ exosomes by flow cytometry, isolated of 1ml of human nasal wash. n=5-6/group.*p<0.05 vs. low 
IgE. 
 
In essence, we could detect miRNA-containing exosomes in murine BALF as well as in 
human nasal wash. We have first hints that the exosomal levels of miR-17 and -21 might be 
associated with asthma development as they were shown to be increased in murine BALF of 
OVA-treated mice, as well as in human nasal washes of patients with higher IgE levels. In 
humans increased miRNA levels also corrobated with higher total exosome numbers. 
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5.7. Uptake of exosomes by target cells in vitro 
5.7.1. Uptake of exosomes by human bronchial epithelial cells 
Exosomes are secreted into various biofluids and can be taken up by specific target cells, 
which are then functionally modified by the exosome content such as miRNAs. By this 
mechanism, various cell types can communicate with each other and also between different 
tissues.  
In order to investigate if the exosomes, secreted by the primary NHBE cells upon IL-13 
stimulus, can be taken up by other airway epithelial cells, we isolated exosomes and labeled 
them with PKH-67. Those exosomes were then incubated with the 16-HBE14o- human 
bronchial cell line. After 24 h many cells containing green fluorescent exosomes could be 
found. There was no difference in the uptake of exosomes that were secreted by primary 
NHBE cells upon IL-13 stimuli or control conditions, nor was a difference between exosomes 
that were secreted to the apical or basal side (Fig. 5.27).  
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Figure 5.27: NHBE exosomes are taken up by 16-HBE14o- cells. 16-HBE14o- cells were cultured for 24 h with isolated 
NHBE exosomes from either apical (upper two panels) or basal (lower two panels) compartments. Upper panel shows cells 
with NHBE exosomes derived from control (untreated) cells, lower panel cells with exosomes from IL-13 treated cells. The 
exosomes were labeled with PKH-67 (green) and the cells with DAPI (blue) for nuclei on glass slides after a cytospin. Outer 
images were merged with a DIC picture to visualize cell membranes. Representative images of n=3 independent experiments.  
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5.7.2. Uptake of exosomes by Jurkat cells 
As one of the most prominent hallmarks of asthma is a chronic inflammation of the airways, 
we wanted to investigate if the exosomes are also taken up by immune cells. Figure 5.28 
shows cytospin images of Jurkat cells, a human T cell line, with clearly visible exosomes 
around the nuclei in the cytoplasm.  
 
 
Figure 5.28: NHBE exosomes are taken up by Jurkat cells. Jurkat cells were cultured for 24 h with isolated NHBE 
exosomes from either apical (left two panels) or basal (right two panels) compartments. Upper panel shows cells with NHBE 
exosomes derived from control treated cells, lower panel cells with exosomes from IL-13 treated cells. The exosomes were 
labeled with PKH-67 (green) and the cells with DAPI for nuclei on glass slides after a cytospin. Right images were merged 
with a DIC picture to visualize cell membranes. Representative images of n=3 independent experiments.  
 
In summary, human bronchial epithelial cells as well as T lymphocytes can take up NHBE 
derived exosomes. In both cell lines we could not observe a difference in the uptake between 
exosomes derived from either control or IL-13 treatments or basal vs. apical exosomes. 
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6. DISCUSSION 
 
The incidence and prevalence of allergies and asthma has been markedly increasing over the 
last few decades. Despite intensive research, the underlying causes are not yet identified. 
Several studies in murine models for allergic airway inflammation (AAI) have been already 
performed. In one of these studies miR-21 was shown to target IL-12p35 and by this influence 
the Th1/Th2 balance. An ablation of this miRNA also ameliorated OVA-induced AAI (87). In 
another study, miR-126 was antagonized in an HDM-induced AAI mouse model which 
reduced the asthmatic phenotype and increased the putative target POU domain class 2 
activating factor, which is important for Th2 functions (83). The same group also found miR-
145 to play a role in asthma development, as an inhibition had a similar anti-inflammatory 
action as glucocorticoid treatment (82). Sharma and colleagues attenuated allergic airway 
disease in mice by inhibiting miR-106a which targets IL-10 (84). One study proposed let-7 to 
be anti-inflammatory due to targeting of IL-13 and showed that administration of let-7 mimics 
to mice attenuated the development of AAI (120). Hence several studies have found altered 
miRNA levels associated with development of allergic airway disease and showed that an 
antagonism or also an overexpression of single miRNAs can ameliorate the asthmatic 
phenotype (82–84,87,120). However, in all these studies the miRNAs were modulated during 
or before the induction of the allergic airway inflammation but not therapeutically in 
established disease, which would correspond to the situation of human patients. Additionally, 
a therapeutic use of miRNAs in humans seems highly unlikely as their ability to bind to 
numerous targets bears the risk to induce massive side effects.  
We therefore exploited whole miRNA profiles to identify so far non-characterized pathways 
where several components are targeted by the dysregulated miRNAs, and investigated the 
relevance for asthma. By this approach we identified a possible down-regulation of 
Creb1/Crtc-mediated transcription by miR-17, -144 and -21, associated with a down-
regulation of the putative target Sec14l3, in two different mouse models for AAI, human 
primary bronchial epithelial cell cultures and human nasal epithelial cells from asthmatic 
children.  
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6.1. The relevance of mouse models to study asthma 
In this study, we used female Balb/c mice and induced allergic airway inflammation by two 
different allergens: ovalbumin (OVA) and house dust mite (HDM). Those models are widely 
used in asthma research, however many therapeutic targets identified in the mouse show no, 
or only limited clinical efficacy in human patients with asthma such as anti-IgE (30), anti-IL-5 
(31,32), anti-IL-4 receptor (33) and anti-IL-13 (34). This can be partly explained by 
fundamental differences between human and mice regarding anatomy, physiology and also 
immune function. Of note, there is no laboratory animal that develops spontaneously a disease 
that can be characterized as asthma. Some larger animals, such as cats, horses, dogs and sheep 
are able to develop bronchial diseases in response to allergens that share some hallmarks with 
asthma (reviewed in (121)). Thus, every laboratory asthma model will be artificially induced 
and might entail different responses depending on the method of sensitization, the used 
antigen and anatomical, immunological properties of the respective animal (reviewed in 
(121)). Big advantages of mice are that they are genetically very well characterized, easy to 
handle, breed and manipulate and also many genetically modified strains are commercially 
available. In contrast to cell culture studies, one can study the complex interplay between 
different cell types and tissues. After sensitization and challenge with allergen, mice exhibit a 
clearly defined Th2-type response in their lungs, accompanied by eosinophilia, airway 
hyperreactivity (AHR) and antigen-specific IgE (reviewed in (122)), characteristics that we 
could also observe in our mouse models. However, there are three major differences to the 
human disease: first humans with asthma always show AHR in response to metacholine while 
mice only do so after allergen challenge; second repeated allergen exposure in sensitized mice 
leads to tolerance rather than a chronic allergic asthma as in humans; third IgE and mast cells 
are not very important for the development of AAI in mice, while they play a pivotal role in 
human asthma (reviewed in (122)).  
Therefore, it is of utmost importance to not only rely on data that are generated in mouse 
models for AAI. In this work, we validated our findings in primary normal human bronchial 
epithelial cells. Cultured at the air-liquid interface, those cells form a pseudo-stratified 
epithelium similar to the in vivo situation (116). They still represent an isolated system 
without interaction of different cell types or extracellular matrix. However, this model could 
be an elegant connection between in vitro and in vivo experiments, being superior to 
immortalized cell lines but easier to handle and to test interventions or treatments than an in 
vivo model. Additionally, we validated our findings in nasal epithelial cells from children with 
allergic asthma and healthy controls.  
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6.2. Joint regulation of Creb1 and Crtcs by miR-17, -144 and -21 
Our group previously found an up-regulation of miR-17 and miR-144, among others, in 
OVA-induced allergic airway inflammation. This study identified dysregulated miRNAs in 
lung homogenate of mice with OVA-induced AAI via quantitative and qualitative 
microarrays. A subsequent in silico target gene research with the 100 top-dysregulated 
miRNAs revealed a miR-17 and -144 up-regulation and a binding to the transcription factor 
Creb1, which was then functionally validated (104). miRNAs tend to simultaneously address 
several key regulatory molecules along one signaling pathway (64) and we identified binding 
sites for both miRNAs and the newly included miR-21 in the 3’UTR of Creb1 co-activators 
Crtc1, -2 & -3. miRNA-21 was newly included as it was the second highest “hit” in our initial 
array (adj. p-value 6.18x10-13), was predicted to target Crtc1 and Creb1, and has been already 
brought into context with allergic airway inflammation (86,87). The putative binding sites 
were validated in in vitro overexpression experiments, validating the previous in silico target 
prediction. Of note, not all three miRNAs did target all factors and sometimes the effects were 
more prominent on protein than on mRNA level and vice versa. To this end, an over-
expression of miR-144 led to a significant decrease in the mRNA levels of all three Crtcs 
which did not affect the protein level. This might be explained by the fact that depending on 
the complementarity of the miRNA sequence to the mRNA, the targets are either degraded, 
deadenylated or the protein translation is inhibited (55). We did observe a small trend for 
Crtc1 and -3 protein down-regulation after miR-17 overexpression although this did not reach 
statistical significance. It might be that, due to the half-life of the proteins a down-regulation 
due to decreased mRNA levels would be only visible at later timepoints.  
The transcription of Creb1 downstream targets has lately been proposed to be regulated in a 
two-hit model (reviewed in (90)): First, Creb is phosphorylated upon stimulation with cAMP 
and binds to CRE sites in promoters and, second, Crtc1, -2 or -3 are dephosphorylated, 
translocated to the nucleus and binds to the bZIP domain of Creb to further enhance gene 
transcription (103). Therefore, a joint miRNA-mediated down-regulation of both factors by 
miRNAs could have an additive effect on the transcription of Creb1 downstream targets, 
which might be relevant for asthma. Along with an up-regulation of miR-17, -144 and -21 in 
lung homogenate of OVA-induced AAI, we detected a slight down-regulation of Creb1 and 
Crtc1 and -3. This was also observed in HDM-induced allergic airway inflammation, 
suggesting it to be independent of the type of allergen. The down-regulation was more 
profound in the HDM-model, which showed a more severe airway inflammation, suggesting 
it to be associated with disease severity. There was no significant change of CREB1 or 
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CRTCs in the nasal cells of children with allergic asthma compared to healthy controls. 
However, the changes in the murine models were investigated 24 hours after the last allergen 
challenge which does not correspond to the long-lasting chronic disease situation present in 
the studied children. In mice, the artificially induced allergic airway inflammation is 
reversible, thus a chronic disease progression could not be studied in our mouse models. 
However, an association of the CREB1 pathway with asthma development and the 
disappearance of CREB1 dysregulation later-on is supported by findings in the primary 
NHBE cells where we saw a down-regulation of both CREB1 and the three CRTCs within 24 
hours of IL-13 treatment which then resolved after 4-7 days on mRNA level. Therefore, we 
speculate that an early down-regulation of the CREB/CRTC pathway in the airway epithelium 
due to asthmatic stimuli affects the transcription of downstream targets such as SEC14L3. 
The dysregulation of the central transcription factors might be reversible, but the putative 
target SEC14L3 might not be. Another reason for the apparent discrepancy of CREB1 
expression in the nasal epithelial cells of patients and the mouse model/cell lines could be that 
we did not stratify patients for medication. Commonly used β2-agonist act via CREB (123) 
and could thus regenerate the expression levels in patients with asthma. To address this 
possibility, future studies in a larger number of children are necessary. Another difference 
between the human and mouse studies was, that in children the expression was investigated in 
nasal epithelial cells as opposed to lung tissue in the murine models.  
The role for CREB signaling in lung diseases and especially asthma is controversial. On the 
one hand, CREB is important for the regulation of immune responses, e.g. by regulating the 
transcription of IL-2, Il-6 and IL-10 (reviewed in (124)). CREB has been shown to be 
decreased after stimulation with “Th2-derived thymus and activation regulated chemokine” 
(TARC) in isolated human T cells (123). Additionally, CREB1 binding activity was shown to 
be negatively correlated with recurrent airway obstruction in horses, a disease that shares 
many similarities with human asthma (125). Similar to these reports, we observed a down-
regulation of Creb1 in two murine models for AAI and also in primary NHBE cells upon 
induction of goblet cell metaplasia by treatment with the Th2 cytokine IL-13. On the other 
hand, two reports show an increase of pulmonary phosphorylated (p)CREB in adult steroid-
resistant or untreated asthma (126) and of total CREB levels in peripheral blood of patients 
with recurrent wheeze (127). These reports, however, are not necessarily controversial to our 
findings of decreased total CREB in bronchial epithelium as total CREB is analyzed in 
different compartments (blood vs lung). Within the pulmonary compartment pCREB and, 
respectively, total CREB levels could be regulated differently.  
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CRTCs have so far mainly been investigated in metabolic processes such as insulin sensitivity 
and energy balance (90,103,128,129), and their involvement in lung diseases or asthma has to 
our knowledge not been investigated so far. Crtc3, together with Creb, has been proposed to 
be essential for transcription of the anti-inflammatory cytokine IL-10 by regulatory 
macrophages (130). In our study, Crtc3 has shown the strongest down-regulation compared to 
Crtc1 and -2 in the HDM-induced murine AAI model and also in the primary NHBE cell 
cultures. Thus, we speculate that the Crtcs might play an important role in chronic 
inflammatory diseases like asthma. In this context, next to macrophages, regulatory T cells 
might be interesting to study as they are impaired in function and number in human asthma 
(131) and they were shown to ameliorate murine AAI after in vivo transfer in an IL-10 
dependent manner (132).  
 
6.3. Identification of Sec14l3 as relevant Creb1 downstream target gene 
We speculate that a miRNA-mediated down-regulation of the very central and ubiquitously 
expressed transcription factor Creb1 could affect different downstream target genes in 
different cell types, which could then lead to different hallmarks of asthma pathogenesis. 
Among the 35 genes which were found to be down-regulated in OVA-induced AAI and 
contain a CRE site in their promoter region, thus being putative Creb1 targets, was Sec14l3. It 
seemed an intriguing molecule to investigate further in the development of asthma as it has 
been proposed to be specifically expressed in the airway epithelium (115) and was found 
decreased in rat allergic airway inflammation (134). By this “cherry picking” approach, other 
Creb1 target genes of relevance for asthma pathogenesis might have been ignored. This will 
be addressed in future studies. For example, the list contains several interesting candidates for 
allergic airway inflammation such as latent TGF-β binding protein 4 (Ltbp4), which is 
involved in TGF-β signaling and thereby might play a role in airway remodeling (133). Fatty 
acid binding protein 5 (Fabp5) has been proposed to play a role in skin barrier function and 
atopic dermatitis (134).  
More than 20 Sec14 family members exist in mammalians and currently they are assumed to 
act as transporters for hydrophobic ligands like α-tocopherol (135). In particular, Sec14l3 has 
been proposed to be a sensor of liposomal lipid-packing defects in the lung (136). The 
assignment of Sec14l3 as Creb target was based on in silico mapping of several CRE sites in 
the promoter region. These CRE sites are highly evolutionary conserved, suggesting that they 
might be biologically relevant. Still, a formal proof that Sec14l3 expression is controlled by 
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Creb1/Crtc-mediated transcription is lacking, as only a very small proportion of palindromic 
CRE sites in promoter regions are truly functional (88). Studies with siRNAs were not 
possible as Sec14l3/SEC14L3 is not expressed in commonly used murine or human lung cell 
lines like MLE-12 or 16-HBE14o-. This might be explained by the fact that these cell lines do 
not contain ciliated cells. SEC14L3 is present in primary NHBE cells after differentiation into 
a pseudo-stratified epithelium at the air-liquid interface but at that stage those are confluent 
and non-transfectable.  
We observed an association of Sec14l3 expression with ciliated cells in immunofluorescent 
stainings of mouse lungs, as well as in the highly significant correlation of SEC14L3 and 
FOXJ1 mRNA levels in differentiating primary NHBE cells. In line with our own findings, 
Shan and colleagues have observed the specific expression of Sec14l3 mRNA in ciliated 
airway cells in murine lungs by in situ hybridization (115). In a previous study, this group has 
shown an inverse correlation of Sec14l3 mRNA expression and allergic airway inflammation 
in a rat model (114), which corroborates our findings in two different models of AAI in mice, 
independent of the type of allergen, and in human paediatric asthma. However to date, it is 
unknown if Sec14l3 has a functional role in ciliated cells or if the observed loss is due to 
trans-differentiation into goblet cells upon asthma development. SEC14L3 has been found to 
be decreased in nasal epithelium of smokers (137) and during human rhinovirus infection 
(138). Taken all these observation into consideration, we propose that the association of 
Sec14l3 loss and goblet metaplasia, which we discovered in this study, might be exploited as 
a biomarker for judging the integrity of the ciliated epithelium. The detection in nasal 
brushings makes it extremely valuable as these cells are easily accessible and can be obtained 
in a non-invasive manner. Thus, the method might even be suitable for infants and children.   
 
6.4. Selection and demographics of paediatric asthma samples 
For our human studies we used brushings of the nasal epithelium of children with allergic 
asthma and healthy controls since the nasal epithelium is in many aspects very similar to the 
bronchial epithelium and has been proposed to be utilized as an easily-accessible surrogate for 
bronchial cells (137,139). In a pilot approach, we investigated changes in miRNA and gene 
expression in seven children with allergic asthma compared to ten healthy controls. We 
decided to study asthma development in children as it is of utmost importance to identify new 
treatment targets that are effective in preventing non-reversible airway remodeling. This can 
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already occur in preschool children, then persist into adulthood (5) and is generally not 
reversible by common asthma medication.  
The 8-12 year old allergic asthma patients were enrolled to the AsthMap study in Washington 
DC (USA) (107,108) and selected based on physician-diagnosed asthma, present at least for 
one year, elevated eosinophil counts ( >4%) and IgE levels ( >150 U/ml) in blood. These 
patients thus showed features which corresponded to the phenotype of allergic asthma that we 
observed in our OVA-and HDM-induced AAI models. The ten healthy control children were 
age-matched and enrolled at the Princess Margaret Hospital for Children in Subiaco 
(Australia). The fact that the samples were collected at two different centers on two different 
continents and are, therefore, different in ethnicity (black for the allergic asthma patients vs. 
caucasian controls) represents the major limitation of this study. There was access to healthy 
control samples in Washington DC, although they were not age-matched and also not of the 
same ethnicity. We assumed that age and puberty might have a bigger influence on the 
expression of our miRNAs and target genes than race or location, so we rather chose the age-
matched Australian controls for our analyses. Despite these limitations, we found a significant 
up-regulation of the three candidate miRNA miR-17, -144 and -21 accompanied by a highly 
significant down-regulation of SEC14L3. However, these findings need further conformation 
especially also in larger patient cohorts.  
 
6.5. Up-regulation of miR-17, -144 and -21 in human paediatric asthma 
In this study, the miRNA regulations in the human paediatric asthma samples were clearly 
stronger than those observed in the murine AAI models. Especially miR-144 had very low 
baseline expression levels in healthy children, but was strongly increased in children with 
allergic asthma. 
We observed a similar low expression of miR-144 in untreated primary NHBE cell cultures 
which increased upon IL-13 stimulus 2-4-fold. This increase was not as high as observed in 
the nasal epithelial cells, which might be due to the relatively short IL-13 exposure of 7 days. 
The expression of miR-144 might be further amplified and perpetuated by a continuous 
stimulus of Th2 cytokines like IL-13 during the development of chronic asthma leading to the 
high expression we detected in the nasal epithelial cells of children with allergic asthma. It 
has been already proposed that the majority of pulmonary miRNAs is physiologically present, 
whereas only a small proportion is generated de novo after induction of disease (140). It is 
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intriguing to speculate that those de novo induced miRNAs have a higher importance for 
disease development or pathogenesis. To our knowledge, miR-144 has not been studied in the 
context of asthma so far, but has been shown to be abundantly expressed in red blood cells, 
together with miR-451 (141). A contamination with red blood cells or a different blood 
content in healthy versus asthmatic samples in our study is unlikely, as the nasal epithelial 
cells were isolated and purified from brushings in an overnight culture step after which any 
red blood cells were washed away. 
MiR-17 and miR-21 were also significantly increased in the nasal epithelial cells of children 
with allergic asthma, although to a lesser extent than miR-144. Up-regulation of miR-21 and 
targeting of IL-12p35 has already been shown in three different models for AAI in mice (86) 
and it has been implicated to play a role in rodent heart failure, lung fibrosis and cancer 
(49,142). The miR-17/92 family is involved in lung development (143) but also in the 
regulation of IL-10 by regulatory T-cells (144). IL-10 transcription has been shown to be 
regulated by Creb1 and Crtc3 (130). Thus, miR-17 might act on IL-10 via targeting Creb1 and 
also Crtc3 and could, therefore, play an important role for the function of regulatory T cells. A 
miR-17 up-regulation, during asthma development might impair IL-10 expression and thereby 
impair the function of regulatory T cells and benefit chronic inflammation.  
 
6.6. Secretion of miRNAs into exosomes 
The initial miRNA profile of dysregulated miRNAs in experimental AAI was performed 
using whole lung homogenate. Thus, it is unknown which cells express and produce the 
miRNAs. One research focus in asthma has been recently turned towards the airway 
epithelium, which is assumed to play an important role in the initiation and perpetuation of 
the disease (reviewed in (38)). Therefore, we studied the expression changes of our three 
candidate miRNAs in primary NHBE cells, cultured at the air-liquid interface.  
To our surprise, we did not observe a major difference in the miRNAs levels after exposure to 
early asthmatic stimuli, namely IL-13 treatment, in the primary NHBE cells compared to 
untreated controls. The expression of miR-17, -144 and -21 increased trendwise after 7 days, 
but this did not reach statistical significance due to high variability. Thus, we asked if the 
primary NHBE cells actively secrete the miRNAs into exosomes to communicate with other 
cell types such as immune cells. If so, after IL-13 treatment an increased amount of miRNAs 
compared to control cells might be ‘packaged’ into exosomes and secreted. In consequence, 
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cellular levels would appear unchanged. When we isolated exosomes from the apical as well 
as the basal side of the cell culture they indeed contained the three candidate miRNAs. The 
exosomal miRNA levels were significantly increased in the basal medium after 24 hours and 
four days and on the apical side after seven days which might suggest a change in secretion 
pattern. It has to be mentioned that it is remains to be clarified if the primary NHBE cells 
actively secrete the exosomes to the apical side, or if the exosomes diffuse through opened 
tight junctions from the basal side since the epithelium might get leaky after IL-13 treatment 
(46,47). Thereby, the apical washes of the cells to obtain exosomes would mimic the BALF 
obtained from patients or mice. 
In line with our study of the NHBE cell line, exosomes isolated from BALF of patients with 
asthma have a different miRNA content compared to healthy controls (74). Kulshreshtha et al. 
showed lately that epithelial cell-derived exosomes are increased during AAI in mice. We did 
not observe this in BALF of our OVA model, although the group sizes were rather small (3 
animals per group) and exosome numbers should be evaluated in more animals. The authors 
further reported, that secretion was induced after IL-13 stimulus in vitro in BEAS-2B cells 
and those exosomes had a pro-inflammatory effect on monocyte and macrophages (145). 
However, this study did not investigate the functional exosome content. We speculate that 
some of the biological effects of the epithelial-cell derived exosomes might be due to 
miRNAs inside exosomes, including miR-17, -144 and –21. Along this line, miR-17, and -21 
levels were increased in exosomes isolated from BALF of OVA-treated mice. In contrast to 
the named study, our data do not point to an enhanced secretion of exosomes after IL-13 
treatment in primary NHBE cells or in murine BALF in the OVA-model. However, we only 
investigated CD63 as an exosomal marker and other markers like CD9 or MHCII might give 
different results. We found all three miRNAs in exosomes isolated from nasal washes of 
children with allergic asthma but also from primary NHBE cultures with and without IL-13 
treatment, suggesting them to be relevant in human asthmatic disease. Unfortunately, we were 
not able to obtain nasal washes from healthy, age-matched controls for comparison. However, 
we found a correlation of a higher exosome amount, exosomal miR-17 and miR-21 in nasal 
washes and IgE levels in serum. This is a first hint that miRNA-containing exosomes in the 
nasal washes are dependent on allergic disease parameters. However, we are aware that 
increased IgE levels may not be the perfect marker to judge asthma severity. Future studies 
will be needed to verify this.  
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6.7. Uptake of exosomes by target cells in vitro 
As we found miRNA-containing exosomes at the apical as well as the basal side of the 
primary NHBE cultures we hypothesized that different cell types might be targeted by apical 
vs. basal exosomes. Apical exosomes could be taken up by e.g. macrophages or epithelial 
cells. The basal exosomes might be accessed by cells present in the submucosa like e.g. 
fibroblasts, smooth muscle cells, but also immune cells like dendritic cells or T cells.  
In cell culture, PKH-67-labeled NHBE-derived exosomes were taken up by a human 
epithelial cell line (16HBE14o-) as well as a human T lymphocyte cell line (Jurkat) within 24 
h. There was no obvious difference between the uptake of apical or basal exosomes or 
between control and IL-13 treated NHBE cells. The regulation and concrete mechanism of 
exosomal uptake by target cells is currently not clear. The nanovesicles often carry receptor 
molecules specific for their target cell on the surface or they can directly fuse with the plasma 
membrane or are phagocytosed (reviewed in (71)).  
After uptake of exosomes by the target cells their content needs to be released and localized to 
different cell compartments to exert its function, another mechanism that is not fully 
understood yet (reviewed in 58). In this study, we did not confirm a functional uptake of the 
exosomal miRNAs to other cells. There are, however, studies in the literature showing that 
miRNAs that are delivered via exosomes are functional in the target cells (72,146,147). 
Hence the precise cargo of exosomes and its functions for allergic airway disease needs to be 
be specified and further investigated in future studies. 
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6.8. Proposed mechanism 
In this work, we identified a molecular axis that potentially contributes to the development of 
allergic asthma in mice and possibly in humans. We propose that miR-17, -144 and -21 not 
only regulate the transcription factor CREB1 but also its co-activators CRTC1, -2 and -3. This 
joint down-regulation might affect the expression of the putative downstream target SEC14L3 
in ciliated airway epithelial cells upon goblet cell metaplasia or other relevant target in other 
cell types such as maybe IL-10 in regulatory T cells or macrophages.  
Summarizing the obtained results, the following model can be proposed: epithelial cells 
secrete exosomes that contain, among others, miR-17, -144 and -21 after IL-13 stimulus e.g. 
during early development of asthma. The exosomes can fuse with other epithelial cells and 
thus transfer included miRNA. This mechanism could distribute early ‘danger’ signals from 
one epithelial cell to many others, and thereby perpetuate and accelerate the disease 
progression in a feed-forward loop manner (Fig. 6.1). The exosomes might also be taken up 
by other cells, such as immune cells including DCs or T cells. A functional miRNA transfer 
and subsequent CREB1/CRTC down-regulation in the recipient cells could affect other targets 
and accelerate the development of a chronic inflammatory allergic airway disease.  
 
Figure 6.1: Proposed model. miR-17, -21 and maybe -144 (human) are secreted by bronchial epithelial cells into the basal 
compartment and also into the apical lumen. In asthma, basal exosomes could also diffuse through the opened tight junctions 
to the apical cell side. Upon uptake by e.g. T-lymphocytes or also in a feed-forward loop manner by other epithelial cells they 
can cause a global down-regulation of the targeted CREB/CRTC pathway in various cell types with different consequences 
for the development of allergic airway inflammation. 
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6.9. Future perspectives 
6.9.1. SEC14L3 as biomarker for epithelial integrity 
The expression of SEC14L3 is lost during changes of the normal airway epithelium, either 
induced by smoking (137), virus infection (115) or - as our data suggest - goblet cell 
metaplasia during asthma development. As SEC14L3 is detectable in the nasal epithelium, it 
may be used as easily-accessible biomarker for the integrity of the respiratory epithelium. 
Especially in preschool children, asthma is often hard to differentiate from transient wheeze, 
hence a marker that enables an evaluation of early changes of the lung epithelium would be 
very useful. Therefore, in order to establish SEC14L3 as a biomarker for changes in airway 
epithelium the SEC14L3 down-regulation in asthma has to be validated in larger patient 
cohorts. Further investigations regarding its function are also warranted.  
 
6.9.2. Epithelial cell-derived exosomes in allergic airway inflammation 
In this study we investigated three candidate miRNAs in murine and human allergic airway 
inflammation. We identified miRNA-17, -21 and -144 as promising candidates to be 
associated with the development of airway inflammation. Finally, we found them to be 
secreted into exosomes by airway epithelial cells thus making the miRNAs accessible to other 
cell types. The target cells of the epithelial secreted exosomes need to be identified and 
validated. They could include other epithelial cells or immune cells such as T cells. The miR-
17, -144 and -21, and others, might be transferred functionally and thereby might regulate the 
CREB1/CRTC-signaling pathway or other signaling pathways in these target cells.  
In future studies the following points should be addressed:  
1) Additional downstream targets of the CREB1/CRTC pathway might give more 
insights into the early development of allergic airway inflammation. One important 
target to study might be IL-10, which was shown to be regulated by Creb1 and Crtc3 
in regulatory macrophages (130). A decrease in this anti-inflammatory cytokine might 
benefit chronic inflammation in asthma. It has been already shown that regulatory T 
cells can ameliorate a murine AAI after in vivo transfer which was dependent on IL-10 
(132). Therefore, Creb1 and the Crtcs should be investigated in regulatory T cells and 
macrophages in murine AAI models and human patients with asthma.  
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2)  Further studies should address if epithelial cells are the only cells secreting those 
miRNAs upon asthmatic stimuli. Furthermore, it should be evaluated if the exosomes, 
secreted after IL-13 treatment, can themselves induce an asthmatic phenotype in 
epithelial cells in terms of goblet cell metaplasia and mediator release. This would 
prove that the miRNA are transferred functionally and that secretion into exosomes is 
crucial for the pathogenesis of asthma, especially for the perpetuation of early 
asthmatic responses. 
 
3) In addition, exosomes derived from asthmatic patients should be thoroughly analyzed 
for their cargo, meaning not only miRNA profiles but also mRNA or protein 
components by high-throughput techniques to decipher the contribution of individual 
components to the airway inflammatory process. Along this line, it should be further 
investigated wether exosomes that are secreted from NHBE cells to the apical side are 
different in cargo and/or surface molecules than those that are secreted to the basal 
side and if they are differentially taken up by other cells.  
.  
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8. Appendix 
8.1. Abbreviations 
A 
AAI: allergic airway inflammation 
Ago: argonaute 
AHR: airway hyperreactivity 
Alum: aluminium hydroxid/magnesium hydroxid 
AMPK: AMP-activated kinase 
APC: antigen presenting cell 
AsthMaP: asthma severity modifying polymorphisms project 
ATF1: activating transcription factor 1 
B 
BALF: broncho-alveolar lavage fluid 
bp: basepairs 
BSA: bovine serum albumin 
bZIP: basic leucine zipper 
C 
cAMP: cyclic adenosine monophosphate 
C. elegans: Caenorhabditis elegans 
CN: calcineurin 
CRE: cAMP-responsive element 
CREB: cAMP responsive element binding protein 
CREM: cAMP response element modulator 
CRTC: cAMP-regulated transcriptional co-activator 
D 
DAPI: 4',6-diamidino-2-phenylindole 
DC: dendritic cell 
DGCR8: DiGeorge critical region 8 protein 
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DMSO: Dimethyl Sulfoxide 
DNA: Deoxyribonucleic acid 
E 
EDTA: ethylenediaminetetraacetic acid 
ELISA: enzyme-linked immuno sorbent assay 
F 
FABP5: fatty acid binding protein 5 
FCS: fetal calf serum 
FEV1: forced expiratory volume in 1 s 
FOXJ1: forkheadbox protein J1 
G 
GAPDH: glycerinaldehyde-3-phosphate dehydrogenase  
GM-CSF: granulocyte-macrophage colony-stimulating factor 
H 
HBSS: hank’s buffered saline solution 
HDM: house-dust mite 
HPRT: hypoxanthine guanine phosphoribosyltransferase 
Hsa: homo sapiens 
I 
Ig: Immunoglobulin 
IL: interleukin 
ILC: innate lymphoid cell 
J 
K 
KID: kinase-inducible domain 
L 
LTBP4: latent TGF-ß binding protein 4 
M 
MAPK: mitogen-activated protein kinase 
MHC: major histocompability complex 
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miRNA/miR: microRNA 
mmu: mus musculus 
MUC5AC: mucin 5AC 
MVB: multivesicular bodies 
N 
n.d.: not detectable 
NHBE: normal bronchial epithelial cells 
nm: nanometer 
NOD: nucleotide oligomerization domain 
Nt: nucleotides 
O 
OVA: ovalbumin 
P 
PAS: periodic acid schiff 
PBS: phosphate buffered saline 
PP: phophatase 
PRR: pattern recognition receptor 
P/S: penicillin/streptavidin 
Q 
qRT-PCR: quantitative real-time PCR 
R 
RISC: RNA-induced silencing complex 
RNA: ribonucleic acid 
S 
Sec14l3: sec14-like3 
Ser: serine 
SEM: standard error of the mean 
SD: splicing domain 
SIK: salt-inducible kinase 
siRNA: small interfering RNA 
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T 
TAD: transactivation domain 
TARC: th2-derived thymus and activation regulated chemokine 
TGF-ß: transforming growth factor-ß 
Th: T helper 
TLR: toll-like receptor 
TRBP: TAR binding protein 
TSLP: thymic stromal lymphopoetin 
U 
UTR: untranslated region 
V 
W 
X 
Y 
Z 
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